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ABSTRACT

Underlying the physical and cognitive deficits consequent of many neuropathologies is one common factor, the loss of neurons. While neurodegenerative diseases,
stroke, and traumatic brain injury arise from a variety of etiologies, they all ultimately result in injury and/or death of neuronal cells and concomitant functional deficits. In the
present work we primarily focus on current and potential treatments for localized lesions, particularly those in the striatum of Parkinson’s disease (PD) or the cortex as in
stroke. First, we discuss a new surgical technique for deep brain stimulator (DBS)
placement, as DBS is a mainstay treatment for movement disorders including PD. We
then explore a novel brain implant capable of rerouting endogenous neural stem cells
(NSCs) within the brain from their usual route to new areas of the brain. These implants
are intended to recruit NSCs and regenerate lost brain tissue in disorders like PD and
stroke. Finally, we investigate the varying effects of nicotine in the brain. Nicotine has
been shown to be both neuroprotective for certain neuronal populations, yet neurotoxic
to others. Therefore, awareness of the influences of nicotine on neural cells is vital for
understanding how nicotine may be of help or detriment to current and prospective
treatments for neurodegenerative disease.

xviii

GENERAL INTRODUCTION OF THE PRESENT WORK
Underlying the physical and cognitive deficits consequent of many neuropathologies is one common factor, the death of neurons. The loss of neurons from either disease or injury leads to a disruption of neural circuitry, improper signal propagation, and
subsequently loss of function corresponding to the affected neural network (1-5). While
neurodegenerative diseases, stroke, and traumatic brain injury (TBI) arise from a variety
of etiologies, they all ultimately result in a loss of neuronal cells and concomitant functional deficits. Disorders resulting from the death of neurons afflict millions of people
worldwide, creating an enormous universal burden medically, emotionally, and financially every year.
Neurodegenerative diseases, stroke, and TBI are leading causes of morbidity
and mortality in the United States and worldwide. The most prevalent neurodegenerative condition is Alzheimer’s disease (AD). There are currently 5.8 million Americans diagnosed with AD and its prevalence is predicted to triple by the year 2050 (6, 7). Further, AD is the most common cause of dementia, accounting for 50–75% of the 44 million people living with dementia worldwide (8). After AD, Parkinson’s disease (PD) is the
second most common neurodegenerative disorder (9) with more than 10 million people
worldwide living with PD (10). Like AD, PD incidence and prevalence dramatically increase with age and are influenced by several environmental, genetic and metabolic
risk factors (11). Other neurodegenerative and neuroinflammatory conditions, such as
Huntington’s disease, amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease), and
multiple sclerosis (MS), constitute thousands more individuals suffering from deficits associated with neuronal death. In addition to degenerative conditions, vascular and
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traumatic injury to the brain can result in neural cell death and concomitant loss of function. Stroke has an annual incidence of nearly 800,000 people in the U.S. and is the 5th
most common cause and death accounting for 1 out of every 20 deaths in America (12,
13). Stroke is also a leading cause of long-term disability worldwide, hindering the mobility of over half of stroke survivors age 65 or older (13). Lastly, over 5 million people
across the globe suffer from serious TBI each year (14). In 2014, there were 2.87 million
TBI-associated emergency department visits, hospitalizations, and deaths in the U.S.,
with 837,000 of these events occurring in children (15, 16). Unfortunately, those who
survive TBI can have negative effects, including impairments related to cognition and
memory, disordered movement, sensory alterations (touch, vision, hearing), or deviations in emotional functioning (personality changes, depression, etc.), that persist for
days post-injury or their entire lifetime (17).
Although each of the therapeutic modalities researched in this work have implications across multiple neurological conditions, the scope of the present work is primarily
concerned with PD. As such, first, we sought to ascertain the patient outcomes following
the current standard of care for advanced-stage PD, namely deep brain stimulation
(DBS). The next aim was to investigate novel therapies for PD and other neuropathologies. Secondly, exploitation of the brain’s innate neuroplasticity for neuro-restorative
was explored. The use of a modifiable, biodegradable brain implant to create an in vivo
migratory pathway for endogenous neural stem cell (NSC) recruitment is discussed.
Then, the possible neuroprotective versus neurotoxic properties of nicotine are discussed; how the effect of nicotine exposure varies on cell type and location throughout
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the brain and the subsequent implications for neurodegenerative conditions and potential confounding effects on aforementioned therapeutic mechanisms.
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CHAPTER 1
SINGLE-STAGE DEEP BRAIN STIMULATOR PLACEMENT FOR MOVEMENT DISORDERS: A CASE SERIES
Introduction
Deep brain stimulation (DBS) therapy has become a mainstay for movement disorders including essential tremor (ET), Parkinson’s disease (PD), and dystonia (18). More
than 160,000 patients have been implanted worldwide and more than 12,000 new patients receive DBS annually (19). Despite decades of experience, patients are frequently offered implantation via multiple, “staged” surgeries. A 2013 international survey
of DBS procedural steps revealed that DBS implantations occurring in the United States
were more likely to be staged than those at European centers (20). In America, 65%
percent of DBS surgeries were staged in 2 days, 22% staged in 3 days and only 13%
were performed in a single stage.
Reasons to separate DBS implantation into multiple surgeries vary, including concerns for increased risk of infection, poor stimulation efficacy, and postoperative confusion leading to increased length of stay, particularly when intraoperative microelectrode
(MER) recording and neurophysiological testing are used (21, 22). In an effort to simplify care and reduce the burden of multiple surgeries on patients, a single-stage approach has been used routinely in Dr. Alastair Hoyt’s practice since his arrival at our institution. We hypothesize that single-stage DBS placement surgery has a similar risk
profile, similar or shorter length of hospital stay, and a similar or reduced rate of reoperations compared to the reported outcomes of surgeries performed in multiple stages.
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Materials and Methods
Patient Selection
After institutional review board approval, a retrospective review of clinical data from
our institution was undertaken for a cohort of patients who underwent DBS implantation
from January 2016 to June 2019. The inclusion criteria included all patients receiving initial placement of DBS system or second unilateral placement (no previous electrode in
that hemisphere). Revision surgeries and routine implanted pulse generator (IPG) exchanges were excluded.
Surgical Technique
All patients underwent preoperative neurology evaluation, neuropsychological testing, and on/off testing in the case of Parkinson’s disease. A stereotactic protocol imaging study was obtained prior to the day of surgery. On the day of surgery, a Leksell
Model G Frame (Elekta, Stockholm, Sweden) was fitted under conscious sedation and a
registration CT scan was performed, followed by computer-aided surgical planning. Depending on the stimulation target and patient, either “awake” placement with MER and
stimulation testing or “asleep” placement under general anesthesia was performed. Intraoperative IPG’s and extension leads were routinely placed before exiting the operating theater. All patients underwent a postoperative CT scan of the head to assess for intracranial complications. As our institution does not allow scheduled nursing assessments more frequently than every four hours in general hospital beds, patients were observed in the intensive care unit for neurological monitoring and blood pressure control.
Initial programming of the stimulation system typically occurred two to four weeks after
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surgery. Patients who did not obtain adequate symptom control, as determined by the
patient and the treating neurologist, were offered DBS revision surgery.
Literature Review
Similar reports were identified by a structured search of the PubMed database and
were summarized (see Appendix B).
Results
A total of 73 patients that met inclusion criteria were identified. The average age
was 65.7 years (range 41–80). Of these patients, 20 were female, and 53 were male.
Mean operative time was 3:50 (range 2:30–5:44) for bilateral placements and 2:58
(range 1:59–4:14) for unilateral placements (Fig 1). The mean length of stay was 1.2
days (range 1–3), with 86.3 percent of patients discharged on the first postoperative
day. The average follow-up after surgery was 23.3 months (range 2.3–50.9). Of the 73
total patients: 46 were treated for PD, 26 for essential tremor (ET), and one for dystonia.
ET was treated with thalamic stimulation and dystonia with pallidal stimulation, while PD
was treated with either pallidal or subthalamic stimulation (Fig 2). There were four patients (5.5%) that underwent “asleep” DBS without MER (Fig 2). The average number of
microelectrode recording passes per electrode placed was 1.55.
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Initial placement of DBS
system or 2nd side unilateral
placement
(no previous DBS in that
hemisphere)
n = 73
Planned
bilateral
placement
Placed
bilateral
n = 56

Planned
unilateral
placement
Placed
unilateral
n = 15

Planned
bilateral
placement
Placed
unilateral
n=2

Planned
unilateral
placement
Placed no
electrode
n=0

Placed 2nd
electrode
n=2
Did not
place 2nd
electrode
n=0
Figure 1. Unilateral Versus Bilateral Placement in Included Patients
This figure describes intended and executed placement of DBS electrodes into unilateral or bilateral hemispheres for all patients.
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Implants
n = 73

Essential Tremor
n = 26

Target
(0 STN; 0
Gpi;
26 (100%)
VIM)

Awake
(88.46%)
Asleep
(11.54%)

Dystonia
n=1

Parkinson’s Disease
n = 46

Target
41 (89.13%)
STN;
5 (10.87%)
Gpi;
0 VIM)

Awake
(97.83%)
Asleep
(2.17%)
Plus 1
reimplantation

Target
(0 STN; 1
(100%) Gpi;
0 VIM)

Awake
(100%)
Asleep
(0%)

Figure 2. Conditions Treated and Brain Targets in Included Patients
This figure presents brain areas targeted by each DBS electrode and whether the surgery was performed with MER (awake) or without MER (asleep). STN = subthalamic nucleus; Gpi = globus pallidus internus; VIM = ventralis intermedius or ventral intermediate
nucleus of the thalamus.
There were fifty-six patients (77%) who underwent bilateral electrode placement
and 15 patients (20%) who underwent unilateral electrode placement. Of these, two patients (3%) were scheduled to undergo bilateral electrode placement but surgery was
halted after placement of the first electrode, one for patient fatigue and one for equipment failure. Both had a second electrode placed in a later procedure.
Table 1 demonstrates the post-operative complications observed. All patients recovered from their complications, with no mortalities or permanent neurological injuries.
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Complications were suffered within 90 days of surgery by six patients (8.2%), while five
(6.8%) suffered a complication more than 90 days after surgery. The most frequent
complication was wound infection (5.5%), which was treated aggressively with the removal of the affected portions of the stimulation system and antibiotic treatment. There
were six patients (8.2%) readmitted within 90 days of surgery (Table 2). Of these six,
four required surgery for treatment of a complication, including two infections, one lead
fracture, and one generator site hematoma. A single patient was readmitted with poorly
defined symptoms which resolved after treatment of pain with nonsteroidal anti-inflammatories. Another patient had bradycardia and hypotension due to cardiac disease not
deemed related to surgery or stimulation. In total, 11 patients (15.1%) underwent additional surgery during the follow-up period, nine (12.3%) for a complication, and the remainder for poor stimulation effect (See Fig 3).

Within 90 Days

>90 Days
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Total (as of the Last

Follow-up)
Number

Percent
(of all
patients)

Number

Infection

2

2.7%

2

Lead
Fracture

1

1.4%

Wound
Dehiscence

0

Hypotension

Percent
(of all
patients)

Number

Percent
(of all
patients)

2.7%

4

5.5%

1

1.4%

2

2.7%

0%

2

2.7%

2

2.7%

1

1.4%

0

0%

1

1.4%

IPG Site
Hematoma

1

1.4%

0

0%

1

1.4%

Total

6

8.2%

5

6.8%

11

15.1%

Table 1. Post-op Complications
Table displays complications suffered by patients within 90 days of surgery and at 90
days or longer after surgery.

Number

Percent
(of all patients included)

Infection

2

2.7%

Lead Fracture

1

1.4%

Hypotension

1

1.4%

IPG Site Hematoma

1

1.4%

Pain

1

1.4%

Total

6

8.2%

Table 2. Post-op Readmissions
Table displays readmissions within 90 days of DBS surgery.
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Lack of effect
n=2

All implants
n =73

No subsequent
surgery other
than IPG
exchange
n = 62

Mechanical
failure
n=2

Subsequent
surgery
n = 11

Infection
n=4

Explanted with
no subsequent
reimplantation
n=0
Removal and
reimplantation of
electrodes
n=2
Lead fracture,
lead replaced.
n=1
Lead short, lead
replaced
n =1
Partial explant
n=0
Total explant
n=4

Wound
Dehiscence
n=1

Explant and later
replacement of
system.
n=1

Other
n=2

IPG hematoma
evacuation n=1
Replacement of
tight,
uncomfortable
extension lead
n=1

Figure 3. Flow Chart of Outcomes
All patient outcomes following DBS surgeries, including whether a return to surgery
was indicated and why.
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There were two patients (2.7%) that underwent a revision for poor stimulation effect. The first was a 66-year-old man with a diagnosis of PD. Pre-operative on/off testing
resulted had revealed significant a reduction of Unified Parkinson’s Disease Rating
Scale (UPDRS) motor scores from 55 to 27. He underwent bilateral pallidal stimulator
placement but had little improvement in symptoms with stimulation. MRI imaging confirmed lead placement in the desired target bilaterally. He subsequently underwent revision of the electrodes from the pallidum to the subthalamic nucleus, again with only
marginal improvement in symptoms.
The second was a 67-year-old man with bilateral upper extremity tremor diagnosed
as essential tremor. He underwent bilateral “asleep” thalamic DBS due to a history of
severe sleep apnea. Substantial improvement was noted in tremor for about 6 weeks
after initial programming, and then tremor appeared to return. Despite multiple programming attempts, the tremor worsened, and he reported persistent headaches. He did not
respond to a trial of levodopa. He ultimately underwent bilateral “awake” lead revision
with MER, although he had relatively little tremor to test intraoperatively. He again experienced no improvement in tremor despite multiple rounds of programming and ultimately elected to have the DBS removed due to persistent headaches.
Discussion
While DBS is a well-established therapy for movement disorders, there is considerable variation in methods of system placement. Attempts to determine the best methods
are hindered by differences in terminology, inconsistent reporting of complications and
outcomes, and the individual practices of surgeons. It is clear, however, that the vast
majority of patients in the United States have been made to undergo multiple staged

12

procedures (20). Little data exists to suggest the practice of staging is superior. Arguments for staging have included improved electrode accuracy, reduced operative time,
and concerns for increased post-operative confusion or other complications (21, 22).
Some authors have referred to “staging” as individually placing only one of two
planned intracranial electrodes at a time, and studies have compared simultaneous bilateral electrode placement with implantation of each hemisphere in two separate surgeries (22, 23). Peng, et al. concluded that there was no significant difference in lead
accuracy between unilateral, simultaneous bilateral, and staged bilateral electrode
placement (22). Petraglia, et al. reported a higher rate of revision within 90 days with
separate unilateral electrode placement than in simultaneous bilateral electrode placement but found no significant difference between these groups in rates of complication
or costs (23). Neither author reported when an IPG was implanted (Appendix B).
Similarly, there have been several published comparisons of “awake” surgery including MER and intraoperative neurophysiological testing with “asleep” surgery under
general anesthesia. A clearly superior technique has not been established (24). Studies
have shown similar outcomes when comparing intraoperative CT (iCT)-guided sub-thalamic nucleus (STN)- or Globus Pallidus (Gpi)-DBS lead implantation to MER-guided
DBS (25), as well as when comparing iMRI-guided GPi-DBS to MER-guided DBS (26),
with some motor outcomes slightly favoring asleep DBS. Mirzadeh, et al. suggested stereotactic accuracy was better under general anesthesia without MER, compared to the
group receiving MER intraoperatively (27, 28). Opposingly, in a retrospective analysis of
awake versus asleep DBS for STN stimulation in PD, Blasberg, et al. found motor function improved faster following awake surgery and axial subitems were worse in the
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asleep surgery group (29). They concluded awake placement was advantageous over
asleep placement in suitable patients. Still, others have reported no significant differences in complications, length of stay, and readmissions between awake and asleep
DBS procedures (30).
Based on personal experience, the senior surgeon of this paper maintains that
MER and “awake” stimulation testing result in superior electrode placement, particularly
in small targets like the STN. As a result, placement under general anesthesia was reserved for patients with significant respiratory comorbidities. In this series, the need for
revision due to poor effect was used as a surrogate for stimulation efficacy. There were
two patients (2.7%) that underwent a revision for poor effect. A patient with a diagnosis
of PD did not have a good response even after revision of the electrodes from the pallidum to the subthalamic nucleus, suggesting that it was not poor placement but the patient’s disease that resulted in lackluster symptom control. A second patient with ET had
a transient response to thalamic stimulation and no improvement after revision of the
electrode, again suggesting a flaw in patient selection and not in electrode placement.
An increased operative time is a logical consequence of single-stage surgery.
While we did observe a longer operative time than is reported in some literature, we did
not observe any serious complications intra- or peri-operatively related to this increased
time under sedation. On one occasion, a bilateral implantation surgery was halted after
placement of a single due to patient somnolence. The patient recovered normally and
received the second electrode in a later procedure. One additional patient had bradycardia and hypotension due to cardiac disease not deemed related to the length of surgery.
In both instances, placement of the IPG in a second procedure would not have
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prevented the event. With an average length of stay of 1.2 days, and 86% of patients returning home on the day after surgery, this increased operative time did not appear to
result in significantly longer lengths of stay (Appendix B).
Further, while difficult to quantify, the single-stage approach reduces each patient’s
total time commitment to DBS placement by avoiding procedures on multiple days. In a
similar effort to streamline the implantation process, Van Horne, et al. (31) performed
cranial access, IPG placement, and extension lead insertion during an initial procedure
and stimulating lead placement using MER in the second stage. An argued benefit was
that an entire system was implanted and ready to program within five days. We assert
that a nonstaged approach provides similar advantages in a single day.
Variation in how complications are reported frustrates direct comparison to other
approaches, but the presented results are similar to published accounts (23, 30, 32-42).
(See Appendix B). In a study evaluating factors associated with postoperative confusion
and prolonged hospital stay following DBS surgery for PD, Abboud, et al. determined
that surgical factors such as implantation laterality, surgical staging, or the number of
MER passes did not influence immediate outcomes (43). A European study showed a
nonsignificant decrease in infection rate in single stage (entire DBS system placed in
one operative session) DBS surgery compared to that in staged DBS surgery (IPG
placed in subsequent surgery) (44). In a retrospective analysis of “asleep” DBS, Chen et
al. found that staging did not significantly affect hardware-related complications such as
infection, erosion, impedance, or lead malposition (30). They also observed a reduction
in hemorrhage or seizures with staging. In another study categorizing staging in the
same manner described in this study, surgical site infections were shown to be similar in
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228 staged and 17 non-staged implantations (6.6% to 5.9%) (40). Their results also
showed similar rates of wound dehiscence and post-op seroma between staged and
non-staged groups (Appendix B).
Perhaps one of the most important factors to many surgeons’ decision to perform
staged DBS implantation is financial. Given the complexities of medical economics in
the United States, it is very difficult to perform an economic evaluation of cost-effectiveness for DBS as a whole, let alone determining the relative cost-effectiveness of singlestage procedures (45). The current payment structure reimburses hospitals more based
on Medicare Severity—Diagnosis Related Group (MS-DRG) codes for staged procedures (46). For example, staged placement of bilateral subthalamic electrodes in one
procedure (MS-DRG 027) with later placement of an IPG (MS-DRG 042) results in a
5.7% greater relative weight for reimbursement than nonstaged placement (MS-DRG
024). This payment structure incentivizes hospitals to mandate surgeons to perform
staged procedures and unfortunately may result in patients having unnecessarily convoluted care.
While admittedly a small sample, this report constitutes one of the larger series of
frame-based bilateral electrode placement with intraoperative MER and neurophysiological testing accompanied by IPG placement in the United States. Direct comparison to
staged approaches is limited by the lack of a control group of staged surgeries at the
same facility by the same surgeon. Anecdotally, the authors have found avoiding multiple procedures to be attractive to patients. It helps to simplify scheduling and to reduce
transportation needs. These factors are particularly attractive when patients may travel
several hours to reach the hospital, such as in rural settings. While no formal
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assessment has been performed, patients frequently report that they prefer a singlestage approach as the longer procedure does not necessitate a longer hospital stay.
Performing a systematic assessment of patients’ attitudes toward a longer, single procedure versus several shorter procedures would help support this assertion.

Conclusions
This series expands the body of evidence suggesting placement of a complete
DBS system during a single procedure, including bilateral electrodes with MER, which
appears to be an efficacious and well-tolerated implantation option. Complication rates,
length of stay, and readmission rates appear comparable with published reports of
staged procedures while the patient avoids multiple procedures.
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CHAPTER 2
CHAPTER INTRODUCTION
The absence of neuro-restorative therapies for disorders of the CNS has motivated research to explore the use of stem cells (SCs) in approaches for cell replacement therapy. Much of the ongoing research in neuroregenerative medicine relies on
the implantation of exogenous SCs, including embryonic pluripotent SCs, embryo or fetal-derived neural SCs, and induced pluripotent stem cells (iPSCs). While successful
outcomes have been reported using exogenous SC grafts in some preclinical (47-53)
and clinical (54, 55) studies of neurological diseases, there remains several complications associated with the implantation of exogenous SCs. Many original issues related
to SC implantation have been mitigated, at least in part, such as tumor formation, immunorejection, death of implanted cells due to lack of stromal support (56) and/or trophic
factors (57) and failed integration of grafts into local neural network (58), however, other
problems have been uncovered such as an indefinite reliance on immunosuppressive
agents (49). Accordingly, there persists an unmet need for new cell replacement approaches that circumvent these issues yet provides an effective method for regeneration of neural tissues.
One potential treatment strategy is to target the brain’s innate regenerative capacity to reverse the trend of cell loss. Although continued post-natal neurogenesis was
first discovered over 50 years ago (59, 60), the fallacy that neurons lost in the adult
mammalian brain could never be replaced persisted. Therefore, modulating the endogenous neuroplasticity of the adult brain remains an underdeveloped resource for neural
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tissue regeneration and could have major therapeutic implications for many neurological
diseases.
While neurogenesis in the adult mammalian brain is relatively limited, endogenous neural progenitors do continue to replicate throughout adulthood. These proliferative niches are primarily in two distinct regions: the subventricular zone (SVZ) located
along the walls of the lateral ventricles and the subgranular zone (SGZ) located in the
dentate gyrus (DG) of the hippocampus. NSCs reside and continue to symmetrically divide throughout adulthood in these regions giving rise to transiently amplifying multipotent neural progenitor cells (NPCs) (59, 61, 62). Neurogenesis in the DG plays a particularly important role in hippocampal-mediated learning (63, 64). In fact, enhanced neurogenesis and survival of newborn cells in the hippocampus is observed in rats trained
on hippocampal-dependent tasks (64), and performance on these tasks is impaired by
inhibition of cell proliferation (65). Newly generated NPCs in the SVZ give rise to another type of neural precursor called the migrating neuroblast, which travel from the lateral ventricles to the olfactory bulb (OB) along the rostral migratory stream (RMS) where
they then mature into neural cells involved in olfaction (60, 66-69). While SVZ NSCs
normally follow this migratory route, brain injuries can stimulate SVZ neurogenesis and
migration of neural progenitors to sites of injury (70-77). Additionally, it has been postulated that traditionally nonneurogenic regions of the brain such as the cortex (78), retina
(79), striatum (80) and substantia nigra (81-83) contain quiescent SCs and/or induce
glial reprogramming to produce NPCs in an innate attempt to repair damaged neural tissues (84-87).
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While the brain’s neuroplastic mechanisms are considerably limited, if the regenerative power of NSCs could be harnessed by targeted recruitment of NSCs/NPCs to
specific brain lesions, therein lies significant neuro-restorative potential. Here we discuss one conceivable mechanism of recruiting NPCs to specific brain lesions to recover
lost function. First, a modifiable biomaterial compatible with NPC migration is presented.
Then, the application of said biomaterial as a cylindrical brain implant for SVZ NSC recruitment to the striatum in hemiparkinson’s rodent model is discussed. Finally, a revised implant design for improved SC recruitment is explored.
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SECTION 1: MODULATING BIODEGRADATION OF A FIBRIN-BASED SCAFFOLD
BY NEURAL CELLS VIA CHEMICALLY IMMOBALIZED APROTININ

Introduction
Whether induced by mechanical trauma, ischemic injury, toxin exposure or neurodegeneration, the death of neurons and loss of axonal connections is central to CNS
injury and subsequent neurological deficits. Restoring damaged or diseased tissue
through cell replacement therapy is a basic underlying principal of regenerative medicine. Cell replacement approaches include, systemic vascular delivery of SCs (88, 89)
or neurogenesis promoting substrates (90-92), direct intracerebral implantation of SCs
(48, 49, 88, 93-97) or bioengineered NSC migratory tracts (98), intranasal administration of therapeutic cells (99, 100), and intraventricular or intraparenchymal administration of growth factors (101-105) or recombinant proteins (106, 107). The efficacy of systemic administration of therapeutic factors is limited by blood brain barrier permeability
and off-target effects (108, 109). These problems are circumvented in approaches that
directly administer cells and/or cytokine into CNS lesions. One obstacle to direct intracerebral administration of chemotactic and/or growth factors is that they can freely migrate/diffuse away from the target area, hindering their therapeutic efficacy (109, 110).
Additionally, a drawback to cell implantation into lesions or methods to enhance neurogenesis and progenitor migration to the site of a brain damage is that transplanted exogenous or recruited endogenous cells have limited survival without stromal support
(111-113).
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These problems have been addressed by incorporating cells and/or therapeutic
substrates into biological matrices, which can then function as implantable scaffolds that
restrict contents to appropriate anatomical locations and provide the needed stromal
support (110, 113-117). One promising application of implantable scaffolds for neuroregeneration has been to induce endogenous stem cell recruitment to other traditionally
nonneurogenic brain regions (98, 111, 118, 119). Various hydrogels, such as MatrigelTM
(120), hyaluronic acid (121, 122) and gelatin (123, 124), have been explored for neural
tissue engineering. While multiple matrix materials have been found suitable to serve as
a scaffold for neural cell migration, survival, differentiation and axon growth (117, 125),
we have found that fibrin possess many desirable properties for CNS implantation (126)
while also allowing for a simple and inexpensive, yet efficient and versatile, methodology for scaffold creation.
Fibrin is a favorable matrix for use as a scaffold in neurological therapies because it is biocompatible (127), viscoelastic (128), plastic (126), has modifiable flexibility
and stiffness (altered by allowing more or less thrombin-induced fibrinogen polymerization) (129) and can be matched to the patient in clinical applications by extraction from
autologous blood (130). Further, fibrin has numerous established neurosurgical and
other clinical applications (131-135). Fibrin is also, however, highly biodegradable and is
rapidly fibrinolysed in the presence of tissues that exhibit robust degradative proteolytic
activity such as neural tissues (136-142). Without intervention of these proteolytic processes, the therapeutic application of fibrin would be severely limited. Fortunately, because of fibrin’s versatility in bioconjugate reactions (143), certain protease inhibitors
capable of slowing or altogether preventing fibrinolysis can be embedded in the
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hydrogel. Aprotinin, a small polypeptide serine protease inhibitor of plasmin and matrix
metalloproteases (144-146) (the degrative enzymes thought to mediate the breakdown
of fibrin (147, 148)) is used in this study.
To prevent the diffusion of aprotinin out of the matrix, rendering the fibrin hydrogel once again susceptible to degradation, aprotinin can be covalently incorporated to
fibrin polymers (146, 149-152). Several methods to accomplish such covalent immobilization of aprotinin within fibrin hydrogels have been previously described (150-153).
However, some of these methods require involved processes, making synthesis of the
aprotinin-linked fibrin scaffolds tedious and timely. One described method involves a
complex, multi-step synthesis of conjugated fibrin-aprotinin via 4-(4-N-maleimidophenyl)
butyric acid hydrazide hydrochloride crosslinking (153). This method, however, yields a
fibrin-aprotinin conjugate with limited stability, experiencing significant in vitro degradation by day 4 in a chick chorioallantoic membrane angiogenesis assay. We suggest that
a more prolonged resistance to degradation will be required for many in vivo or clinical
applications, particularly in environments the exhibit robust proteolytic activities like the
brain. An alternative method to achieve covalent immobilization of aprotinin into fibrin
involved the generation of a recombinant version of the protease inhibitor, thus necessitating a bacterial expression system and purification of the material prior to pre-clinical
or clinical use (150). Unfortunately, it was also not apparent that this construct could be
easily tuned to yield matrices with varying stability against degradation. We postulate a
tunable architecture would be more suitable for use in a variety of regenerative applications.
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Despite its widespread use in experimental and clinical neurobiology, the stabilization of fibrin hydrogels in the CNS is underreported. We present an efficient and versatile method for the covalent incorporation of aprotinin into fibrin via incorporation of
chemical crosslinking agent disuccinimidyl suberate (DSS). The present method does
not require specialized laboratory expertise, equipment, or reagents. And importantly,
can be optimized to yield matrices of desired biological half-life in neural tissues, ranging from fibrin stability of days to weeks in vitro and in vivo.

Materials and Methods
Subventricular Zone Neural Progenitor Cell (SVZ-NPC) Culture
All animal procedures were performed following an approved protocol from the
Institutional Animal Care and Use Committee of Marshall University. Cell culture reagents were from Life Technologies and growth factors were from R&D Systems. SVZNPCs were isolated from 200-275 gm female Sprague-Dawley rats according to standard methodology (154). The cells were maintained in DMEM/F12 media supplemented
with B27/N2 according to the manufacturer’s recommendation, penicillin/streptomycin
(100 U/ml), 2 µg/ml heparin, 20 ng/ml bFGF-2, and 20 ng/ml EGF. The cells were maintained on a constantly rocking (30 rpm) platform at 37°, 5% CO2 in 6 well non-tissue
culture treated plates. Spheroids and aggregates were enzymatically dissociated into
single-cell preparations using Accutase® approximately every 2 weeks for propagation
or as needed for use in experiments. To accomplish this, spheroids were recovered
from culture and allowed to settle at 1 x g for five minutes. The supernatant was removed and 1 ml of Accutase® was added to the sample which was incubated at 37º for
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10-15 minutes with frequent trituration. The homogenous cell suspension was centrifuged for 5 minutes at 500 x g at ambient temperature. The pellet was either resuspended in the maintenance media described above or used for seeding tissue culture
wells containing fibrin domes (vide infra).

Preparation of fibrin matrices
All stock components were dissolved in PBS unless otherwise noted. Solutions
containing fibrinogen (from bovine plasma, Sigma-Aldrich) and varying amounts of aprotinin (from bovine lung, Sigma-Aldrich) were prepared as 20 µl (final volume) aliquots on
Parafilm® in a humidified chamber. When crosslinker was used, disuccinimidyl suberate
(Pierce Chemical Co.) was freshly dissolved in dry DMSO (dried over 4Å, 40 mesh molecular sieves) and added to the sample at a final concentration of 50 µM. The final fibrinogen concentration 36 µM and the fibrinogen-fibrin conversion was initiated by the
addition of 0.1 U thrombin (1 µl, from bovine plasma, Sigma- Aldrich). To prepare
domes for cell culture experiments, the preparation was quickly transferred into individual wells of 24-well tissue culture plates and the sample allowed to polymerize for 20-30
minutes before the careful addition of media and cells. Fibrin cylinders for surgical implantation were prepared in a similar manner, except that fluorescent fibrinogen (Alexa
488 fibrinogen, Life Technologies) was admixed with the preparation at a final concentration of 0.15 mg/ml. Polymerization was initiated via thrombin and the sample was
quickly drawn into quartz tubes (Fiber Optic Center, dimensions, 0.70 mm inner diameter [i.d.] x 3.5 cm) such that a 6 mm long cylinders were crafted.
In vitro assessment of fibrin stability with SVZ-NPCs
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Approximately 1 x 104 cells were seeded into wells containing fibrin domes with
or without aprotinin and/or DSS, in 600 ul aliquots of DMEM/F12, B27/N2, penicillin/streptomycin. Media was changed every 3-4 days. Mosaic photomicrographs were
taken of each dome at days 2, 3, 4, 7, 9 and 14. Images were acquired using a Zeiss
Axio Observer microscope (10x objective) outfitted with a Zeiss PM S1 live cell incubator, controlled by AxioVision software. Dome area was measured using this same software program.
Brain implantation of Fibrin Cylinders
Fibrin cylinders were made as described above and a small disc of PVDF (0.56
mm dia., Berkley) was inserted into the quartz tube and served as a plunger head. Anesthesia of female Sprague Dawley rats (250-300 gm) was induced via 5% isoflurane
and maintained with 2.5% isoflurane (oxygen carrier flow rate maintained at 0.8 L/min).
The animal’s scalp was shaved and, after fitting the animal into a Kopf stereotaxic
frame, the scalp was swabbed with Betadine®. An approximately 2 cm incision (anteriorposterior) was made in order to expose the skull bregma and lambda suture landmarks.
The exposed skull was scrubbed with 3% H2O2 to clear away subcutaneous connective
tissue. Two stereotaxic frame manipulator arms were used, one on each arm of the
Kopf “U” frame, and both were angled 17º to the right of midline. To implant a cylinder
into the right hemisphere, the tip of the fibrin cylinder-containing quartz tube (on the first
manipulator arm) was moved, relative to the bregma, 0.13 cm anterior and 0.30 cm right
of midline. A small hole was drilled using a round dental bur at the location corresponding to these coordinates. The dura was gently pricked with a 25-gauge needle and the
tube driven 0.73 cm down the dorsoventral axis on an angle 17º off midline to the right.
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A 0.5 mm stainless steel wire, affixed onto the second manipulator arm positioned directly above the first arm, served as a plunger and was lowered into the fibrin cylindercontaining tube. The plunger was lowered until the plunger head reached the top of the
fibrin cylinder. The plunger was held immobile by the second manipulator arm while the
quartz tube was slowly raised (1/4 turn/45 seconds) via the first manipulator. This maneuver results in the fibrin cylinder being placed in the brain along a predetermined path
as the quartz tube is pulled out of the brain with the plunger holding the cylinder in
place. The fibrin cylinders are implanted such that they transect the RMS containing
SVZ migrating neuroblasts (a location chosen as it exposes the fibrin implants to the
same endogenous progenitor cells being investigated for neuroregeneration therapies
(98)). After complete extraction of the quartz tube and a five-minute incubation period,
the plunger was slowly removed, the skull hole plugged with bone wax and the scalp
closed with absorbable sutures plus Histoacryl®. Animals were injected with dexamethasone (0.4 mg/kg s.c. in 0.9% sterile saline) once at the time of anesthesia induction
and then each day for four days post- operatively. For pain management, animals were
injected with buprenorphine (0.15 mg/kg s.c.) immediately after surgery and then daily
for two additional days.

Brain extraction and preservation
The first cohort of animals were sacrificed three weeks post-implant and brains extracted as described below (these brains samples were ultimately cryosectioned, imaged, and two-dimensional (2D) areas of remaining fibrin calculated). The second
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cohort of animals were sacrificed at eight weeks post-implant and brains extracted
(these brain samples then underwent non-destructive in situ imaging using tissue clearing and surface area of remaining three-dimensional (3D) cylinders were measured).
Animals sacrificed by bilateral pneumothoracotomy, fixed via transcardial perfusion with
0.9% NaCl with 2U/ml heparin followed by 4% PFA. Brains were then carefully removed
and underwent overnight post-fixing in 4% PFA.

Cryosectioning and imaging of brain samples
Following overnight post-fixing in 4% PFA, brains from the first cohort of animals
were equilibrated in 30% sucrose until no longer buoyant and sectioned into 20 μm sections using a Leica cryostat. Sections were mounted on SuperfrostTM Plus slides
(Fisher Scientific) using Fluoro-Gel II with DAPI (Electron Microscopy Sciences) as a
mountant, covered with #1 coverslips and sealed with clear nail polish. Sections were
observed on a Zeiss Axio Observer fluorescence microscope using Zeiss filter cube
38HE (470/40 excitation; 525/50 emission; 495 split). The area of fluorescent fibrin remaining in the section was quantitated using AxioVision software (Zeiss). Unfortunately,
this method had two major downfalls. The first being that the freezing and manipulation
of thin tissues left the embedded fibrin susceptible to falling out of the samples. Secondly, this method could only render a 2D view of a portion of the fibrin cylinder at a
time for imaging. Therefore, the second cohort of brains collected underwent an alternative technique for imaging and analysis (vide infra).
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Passive clearing and refractive index matching of brain samples
Tissue clearing methodology based on/adapted from previously published work
(155, 156). Briefly, following post-fixation in PFA, lipid-clearing of whole brain samples
was attempted using passive CLARITY technique (PACT), without the use electrophoretic tissue clearing as to not induce undue tissue swelling and disrupt brain implants.
Intact brain samples were desired at this time as preliminary work revealed complications in attempts to cryosection portions of histological tissue that contained the cylindrical fibrin implants (notably, portions of the fibrin cylinders falling out of the manipulated
tissues slices). As collecting measurements of remaining, undegraded fibrin within the
brain samples was necessary, we sought an approach that would allow for imaging
without the need for sectioning across the fibrin implants.
Whole rat brains were incubated at 4°C overnight in hydrogel monomer solution
(4% acrylamide, 0.05% bis-acrylamide and 4% PFA in PBS) supplemented with 0.25%
photoinitiator 2,2'-Azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride (VA-044, Wako
Chemicals USA, Inc.) thermal initiator. The hydrogel-infused samples degassed with nitrogen for approximately 30 minutes to ensure consistent hydrogel polymerization.
Samples incubated for 2–3 hours at 37 °C to initiate tissue-hydrogel hybridization via
VA-044 thermal initiation.
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Once tissues were successfully cross-linked to acrylamide, excess hydrogel was
gently removed with a Kimwipe and samples were transferred to perforated 50 mL conical tubes to bathe in clearing solution. To extract lipids, hydrogel-embedded brains were
then incubated in sodium dodecyl sulphate (SDS) detergent clearing solution (4-8%
SDS in 200 mM boric acid solution, pH 8.5 with NaOH) for 5 months. However, at this
time it became evident that lipid clearing would not produce completely transparent
brain tissue through these means for the internal regions of the whole brain samples.

Figure 4. Cleared Brain Samples
Photographs of hemisected coronal brain slices before CLARITY/RIMS (far-left) and after
(middle). Far-right image is expanded view from middle image, showing an intact fluorescent cylindrical implant within a single 2mm brain slice (as described in methods).

Taking into account surgical coordinates and brain surface landmarks, brains
were hemisected and sliced to 2mm thickness using a brain mold and sharp razor
blade. The sections were made so that the entire fibrin cylinder, if remaining, would be
contained within one slice preparation (Fig 4). The 2 mm rat brain samples were then
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returned to 50ml tubes containing clearing solution for 2 weeks. At that time tissue samples appeared relatively transparent and were washed with PBS and moved to refractive index matching solution (RIMS). RIMS imaging solution contained 40g of Histodenz
(Sigma D2158) in 30 ml of 0.02 M PB with 0.1% tween-20 and 0.01% sodium azide, pH
to 7.5 with NaOH, resulting in a final concentration of 88% Histodenz w/v. Samples
were incubated in RIMS throughout imaging.

Imaging of fibrin brain implants
Images were acquired using Zeiss light sheet microscopy. The 2 mm cleared
brain slices were affixed to a straightened section of 4-5 staples using superglue such
that the brain sample was suspended by their upper pole and the portion to be imaged
hung below. The staple was magnet mounted into a 5X clarity chamber. Images collected using the following parameters: detection objective – EC Plan-Neofluar
5x/0.164908000123; Illumination Objective – LSFM 5x/0.1; 488 nm laser at 20% power;
Camera Exposure Time 30 ms; Light sheet thickness 7.32 µm; zoom 0.56; single-side
illumination.
Image and statistical analysis
Images were imported to Imaris (Bitplane) software for surface area analysis of
cylinder 3D reconstructions. Surface area of remaining 488Alexa fibrin cylinders for
each concentration were compared to each other. Comparisons to starting surface area
could not be determined due to the swelling the occurs during the CLARITY process.
Graphpad Prism was used for all statistical analysis.
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Results
To establish a baseline for these studies, fibrin alone was cultured with SVZ- NPCs
and the rate of degradation determined. The data indicate rapid degradation of the matrix, with only 20% of the dome remaining at Day 5 and no observable material remaining after seven days (Fig. 5A and Fig. 6). Very little additional stability was observed
when 30 µM aprotinin was non-covalently included in the fibrin dome (Fig. 5C and Fig.
6). This supports a number of reports indicating that the inhibitor (Mw= 6500 dalton) rapidly diffuses out of fibrin or other matrices (150, 153, 157). Figure 5B displays results
observed when DSS alone was added to the fibrin. Interestingly, the crosslinker alone
imparted slight resistance to SVZ-NPC mediated degradation (Fig. 5B and Fig. 6), suggesting that the DSS crosslinked structure of fibrin is itself somewhat more resistant to
proteolytic degradation compared to native fibrin. Finally, aprotinin, at 30 µM and covalently crosslinked into fibrin, completely resisted degradation throughout the duration of
this experiment (7 days; Fig. 5D and Fig. 6). Additional experimentation (data not
shown) revealed that fibrin domes crosslinked with 30 µM aprotinin were completely intact up to 3 weeks in culture.
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Figure 5. Photomicrographs of Fibrin Domes in SVZ-NPC Culture
Fibrin domes containing aprotinin and/or DSS were cast in 24 well tissue culture plates
and seeded with SVZ- NPCs. On the indicated day a 12 x 15 mosaic photomicrograph
of each dome was obtained. (A) Fibrin only. (B) Fibrin plus 50 µM DSS. (C) Fibrin plus
30 µM aprotinin. (D) Fibrin plus 50 µM DSS and 30 µM aprotinin. The dark structures
seen in some of the images are aggregates of cells that are out of the focal plane.
Scale bar, 500 µm.
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Figure 6. Degradation Rates of Fibrin Domes
Rate of degradation of fibrin-based domes containing immobilized or diffusible aprotinin
in SVZ-NPC culture. Samples as described in Figure 5 were analyzed by assessing the
area of fibrin dome remaining on a specific day relative to the area of that dome at the
start of the experiment and plotted as percent dome remaining according to time.

An in vitro aprotinin dose-response experiment was performed over a 14-day period to determine whether it would be possible to develop fibrin hydrogels of varying degrees of stability in the presence of SVZ-NPCs. It was observed that fibrin stability could
indeed be readily controlled depending upon the concentration of DSS-crosslinked
aprotinin that was incorporated into the hydrogels (Figure 7 & 8). At concentrations 30
and 60 µM, domes were essentially completely resistant to degradation for the entire
duration of the experiment. At lower concentrations, the dome half-life varied in a dosedependent manner with concentrations below 10 µM showing significant degradation
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after 1 week. This indicates that it is possible to fine-tune fibrin matrices to a particular
stability for in vitro NSC experimentation.

Figure 7. Aprotinin Mediated In Vitro Stability of Fibrin in a Dose-Dependent
Manner Over the Course of Fourteen Days
Fibrin domes containing fibrin alone, fibrin with DSS, or fibrin with increasing
amounts of aprotinin ± 50 µM DSS were cast in 24 well tissue culture plates, incubated with SVZ-NPCs for the indicated number of days, and the area of dome
remaining on the indicated day.
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Figure 8. Aprotinin Mediated In Vitro Stability of Fibrin in a Dose-Dependent
Manner

Fibrin domes with or without DSS and with increasing doses of protease inhibitor
aprotinin were seeded with SVZ NPCs in cell culture. Statistically significant differences between areas of fibrin domes remaining at experimental endpoint (day 14)
are presented. Data are mean ±SEM; Ordinary One-way ANOVA
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Aprotinin mediated in vivo stability of fibrin in a dose-dependent manner was also
demonstrated (Fig 9, 10 & 12). All animals recovered fully after the procedure and there
were no obvious behavioral sequelae. The first in vivo cohort (animals sacrificed 3weeks post-implant) demonstrated increased resistance to degradation with increasing
crosslinked aprotinin included in the fibrin implants (Fig 9 & 10). With the 0.075 µM
aprotinin containing implant being nearly completely degraded, Cylinders that were cast
with 0.75 µM or 0.075 µM aprotinin were significantly degraded based on Alexa-488

0.075 μM

0.75 μM

7.5 μM

Figure 9. Concentration Dependence of Crosslinked Aprotinin on Fibrin Stability in Brain Implants
Fibrin cylinders made with Alexa 488-fibrinogen and containing increasing amounts
of aprotinin crosslinked with 50 μM DSS were implanted into rat brain striatum (right
hemisphere). Animals were sacrificed three weeks following surgery and brain sections visualized for Alexa 488 fluorescence. (A) Implanted cylinder containing 0.075
μM aprotinin. (B) Implanted cylinder containing 0.75 μM aprotinin. (C) Implanted cylinder containing 7.5 μM aprotinin. Scale bar, 2 mm.
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containing fibrin that was visualized with brain sections collected (Fig 10). When calculations of percent remaining are calculated based on images provided (Fig. 9), cylinders
that were cast with 0.75 µM or 0.075 µM aprotinin were 80% and 95% degraded, respectively. These results were complicated by the inability to visualize the intact fibrin
cylinder as a whole. However, brain sections immediately adjacent to those depicted
(Figure 9) were completely void of Alexa 488 fluorescence in the 0.075 µM and 0.75 µM
aprotinin brains. Percent remaining, however, could not be determined for the 7.5 µM
aprotinin cylinders due to problems previously discussed. Nonetheless, it is evident that
a substantially larger amount of Alexa 488 containing fibrin is detectible in the 7.5 µM
aprotinin sample, with an implant area over 3X greater than the next highest aprotinin
concentration.

Figure 10. Quantitation of Fibrin Stability in Brain Implants
The area of the implanted fibrin matrix was determined from the images shown in
Fig. 6 and presented as total pixels as a function of aprotinin concentration.
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For the second cohort (animals sacrificed 8-weeks post-implant and whole brain
clearing), 2D representative images of fibrin cylinders containing 30 and 60 µM aprotinin
plus DSS are presented (Fig 11). Graphical representation (Fig 12) and raw data (Table
3) of the surface area remaining for each implanted fibrin cylinder containing increasing
amounts of chemically crosslinked aprotinin are shown. The data show a dose-dependent resistance to degradation of fibrin in the neural environment with the use of proteolytic inhibitor aprotinin. On average, 46% more Alexa488 fibrin was detected in 60 µM
samples than in 30 µM at week 8 post-implant. We suspect that if the fourth 10 µM
aprotinin cylinder containing brain was not damaged and would have been included in
the analysis that it would have followed the dose-dependent trend. Moreover, these

Figure 11. Two-Dimensional Representative Image of Fibrin Cylinders Used for
3D Reconstruction and Surface Area Analysis
data also reveal significant variability between animals. This may be due to any number
of biological variabilities such as quantity of SVZ NPCs, varying proteolytic activity or
other unknown differences. These data also demonstrate the usefulness of using the
simple technique of chemical-crosslinking via addition of DSS to the fibrin/aprotinin mixture before casting implantable matrices.
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Figure 12. Aprotinin Concentration Dependence of Fibrin Stability Following
Brain Implantation

Alexa 488-fibrinogen containing cylinders with increasing amounts of aprotinin crosslinked with 50 µM DSS were implanted in rat brains such that the cylinders transect
the endogenous path of SVZ NPCs and surface area of cylinders remaining 8 weeks
after surgery were measured. All datapoints are shown ±SEM; *p<0.05; One-way
ANOVA
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Surface area of Fibrin Cylinders Following CLARITY and 3D Reconstruction
Aprotinin
concentration

60 µM

30 µM

10 µM

0 µM

sham

2,031,080

0

-

0

0

4,410,160

261,334

0

0

0

Surface area of
cylinder
remaining
in each brain
(µM2)

7,008,460

4,521,290

2,862,760

0

0

11,835,200

6,893,400

5,892,140

2,862,760

0

Averages (µM2)

6,321,225

2,919,006

2,918,300

715,690

0

Table 3. Raw Data In Vivo Experiment
Four brain samples were obtained for each treatment. Brains passively cleared and
cylinders imaged in their entirety (without sectioning) using light sheet microscopy.
The remaining Alexa488 for each cylinder at experimental end-point (post-implant
week 8) are shown. One 10 µM sample was damaged and therefore not included.
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Discussion
There are many synthetic and natural polymers that have been used as matrices for
the therapeutic delivery of cells, proteins/peptides, or other compounds into tissues. Our
laboratory proposes that fibrin is an ideal material for such applications, especially those
aimed at furthering our understanding of neurological disorders and the development of
associated novel therapies. It is biocompatible and biodegradable, thus appropriate for
implantation in clinical applications. Fibrin is easily molded into desired 3D structures,
pliable, and readily modified via chemical crosslinking agents such as the amino-directed reagent described here. It is cast and gelled under mild conditions enabling the
incorporation of labile peptides, proteins, and cells. Fibrin-based matrices of various mechanical strengths can be prepared by varying the thrombin/fibrinogen ratio (158, 159),
therefore fibrin can be cast into a very similar “softness” as brain tissue. Importantly,
mechanical cues have been shown to affect many neuronal processes (160) and previous reports indicate matrices with compliance comparable to brain tissue select for and
support neuronal growth (158, 161). This report further strengthens the argument that
fibrin holds potential as an implantable matrix into the CNS; we demonstrate that degradation rates can be customized by incorporating specific amounts of immobilized aprotinin. Applications such as the transient delivery of a neurotrophin may require a rapidly
degraded matrix, while, on the other hand, providing a stable extracellular matrix for regeneration of a complex structure such as a neural migratory pathway may necessitate
several weeks of stability.
Fibrin biodegradation or fibrinolysis is a natural process mediated by both secreted
(e.g. plasmin) and cell-associated (e.g. matrix metalloproteases) proteolytic enzymes
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(147, 162). Aprotinin has been shown to inhibit the activity of both classes of proteases
secreted by many cell types including neural cells (150). Robust fibrinolytic activity,
thought to be critical in the natural response to stroke (138), is exhibited throughout the
brain and aprotinin may provide a solution for the challenge natural fibrinolysis poses on
the utilization of fibrin-based scaffolding in CNS regenerative therapies. This study
aimed to develop a biocompatible, customizable, easily reproducible, and implantable
matrix based on fibrin.
We found that fibrin was rapidly degraded when seeded with SVZ NPCs. The noncovalent addition of aprotinin to the fibrin solution provided no anti-fibrinolytic support,
as suspected based on previous reports of rapid diffusion of the 6.5kDa aprotinin out of
the fibrin hydrogels (150, 153). Incorporation of disuccinimidyl suberate (DSS), a noncleavable, homobifunctional amino crosslinking agent (163), was successful at immobilizing aprotinin in the fibrin matrix and thus allowing aprotinin to prevent fibrinolysis in a
dose-dependent manner. This trend was observed in both SVZ NPC culture and rat
brain implantation models.
As the stabilization of the fibrin matrix was directly proportional to the concentration
of proteolytic inhibitor used, this allows for a “tunable” fibrin scaffold. An important quality as we postulate that for their use in potential neuroregenerative therapies, neural implants must be stable enough to provide a suitable time frame for a desired cellular response to cues provided by the implant, but must eventually degrade completely to yield
to de novo complex cellular structures. Significantly, over the period between surgery
and sacrifice, there were no obvious deleterious postoperative effects of the implants on
the animals in terms of overt behavior, tumorigenesis, or significant brain damage.
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Conclusion
The current study demonstrates the feasibility of bioengineering implantable fibrin
matrices to a modifiable and predetermined degree of stability against biodegradation
within the CNS. The method of covalent incorporation of the proteolytic inhibitor, aprotinin, into hydrogel scaffolds presented here is simple, inexpensive, and easily reproducible. Stabilization of fibrin implants in vitro and in vivo is critical for ongoing and future
research investigating applications in tissue engineering.
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SECTION 2: IN VIVO NEURAL TISSUE ENGINEERING: CYLINDRICAL BIOCOMPATIBLE HYDROGELS THAT CREATE NEW NEURAL TRACTS IN THE ADULT
MAMMALIAN BRAIN
Introduction
Individuals suffering from neurodegenerative disorders (e.g. Parkinson’s, Alzheimer’s, or Huntington’s) or brain injuries (e.g. stroke or traumatic brain injury) have
few effective treatment options. Therapies based on the regeneration or replacement of
appropriate neurons have been proposed and many of these rely on implantation of exogenous stem cells into the lesioned area of the brain (54, 126, 164-167). To date,
these approaches face serious problems such as immunogenicity, tumorigenicity, functional ineffectiveness, cell availability, and ethical concerns (168-170). We describe in
this study, an alternate and potentially transformative procedure for targeted neural cell
replacement that is based on the recruitment and guidance of endogenous neural stem
cells directly from their natural niche into a specific region of interest. Harnessing these
preexisting neural progenitors in vivo will bypass the numerous concerns associated
with exogenous cell transplantation. When reduced to practice, this unique approach
will have tremendous ramifications for patients suffering from neurological disorders
who currently face a paucity of beneficial therapies.
This innovation is derived from our understanding of adult neurogenesis in the
mammalian brain, which consists of a coordinated series of overlapping steps, including
proliferation, differentiation, migration, neuritogenesis, axon guidance, and integration
(171). Induced adult neuro- genesis has been demonstrated to be a natural response to
various activities such as exercise (172) or neurological disorders such as stroke (173-
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176) or traumatic brain injury (75, 176, 177), and this has led to the belief that endogenous neural stem cells can be harnessed to repopulate dysfunctional or lesioned
nonneurogenic regions of the brain (76, 178). Studies using cultured neural stem cells
and genetically engineered animals have identified numerous neurotrophins and extracellular matrix (ECM) components that appear to mediate the maturation of endogenous
NPCs into neurons (179, 180). However, few reports integrate this knowledge into an
application that can be used to engineer an effective means to recruit these cells to regenerate neural tissue, especially using an in vivo approach. The full potential of therapeutic endogenous neural stem cells requires efficient cell recruitment, targeting, neural
subtype-specific differentiation, and long-term cell survival. The results presented in this
study represent an important contribution toward achieving these goals.
A renewable source of endogenous neural stem cells is the adult mammalian
SVZ. Much of what we currently know about neurogenesis has come through studies of
the SVZ/RMS/OB pathway (181, 182). SVZ-derived neural progenitor cells (SVZ-NPCs)
are the likely source of nascent neurons, which arise in the typically nonneurogenic striatum following exercise or injury (75, 172-177). This supports the notion that SVZ-NPCs
are naturally rerouted to typically nonneurogenic regions in response to an insult to the
brain. While a vital observation, the number of SVZ-derived cells naturally recruited to
lesioned areas is too low to expect significant therapeutic efficacy in the case of most
neuro-degenerative diseases or brain injury.
Recent efforts to deliberately recruit endogenous NPCs into nonneurogenic areas of the brain have met with some success. This approach was in the form of hyaluronic acid engineered to contain neurotrophic factors, made as an injectable low
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viscosity polymer (183), which increased neurogenesis in rat cortex and striatum after
injection into these regions (184). These authors suggested that the source of new neural cells may be endogenous quiescent NPCs rather than a neurogenic niche such as
the SVZ.
The goal of this report is to present research describing a means to reroute and
retask endogenous SVZ-NPCs from the RMS to populate nonneurogenic brain regions
with new neural cells. Our approach was to develop an implantable, biocompatible, and
biodegradable fibrin matrix, which was readily modified to contain judiciously chosen immobilized factors such as neurotrophins, ECM molecules, and aprotinin. Our goal, upon
implantation into the brain, was to provide an environment that would create a new migratory path from the renewable neurogenic niche of the SVZ/RMS to a new and distant
target region. We chose to include both neurogenic [nerve growth factor (NGF)] and angiogenic [vascular endothelial growth factor (VEGF)] factors in the implantable microenvironment since both developmental processes are inextricably linked to the creation of
neural migratory paths (185-188).
We believe that fibrin is an ideal biomaterial for these implantable matrices; it is
readily chemically modified to covalently incorporate bioactive peptides and proteins
(143); it is biochemically similar to extracellular proteins found in the brain (128, 158);
fibrin is biologically compatible and is degraded by well-known and inhibitable proteolytic processes (147, 162); and, it is used clinically in the form of fibrin sealant and has
low immunogenicity (132, 189). Furthermore, several groups have successfully used fibrin hydrogel injected into animals to address spinal cord and peripheral nerve injury
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(143, 190-195). Finally, it seemed logical to create this implantable biomaterial in the
form of a cylinder since the RMS is, in fact, cylindrical.

Materials and Methods
Preparation of implantable cylindrical scaffolds
Fibrinogen (Sigma-Aldrich, St. Louis, MO) was dissolved in phosphate-buffered
saline (PBS) at a final concentration of 64 µM, degassed, and stored in aliquots at 80°C.
An 8 µL aliquot of fibrinogen was placed on a square of Parafilm® to which was added
aprotinin (15 µM Sigma-Aldrich), laminin I (100 µg/mL Trevigen, Gaithersburg, MD), carrier-free VEGF (10 µg/mL final concentration; R&D Systems, Minneapolis, MN), and
carrier-free NGF (10µg/mL final concentration; R&D Systems). The volume of the sample was brought to 18 µL with PBS. The homobifunctional crosslinker disuccinimidyl suberate (DSS; Thermo Scientific Pierce, Rockford, IL) was dissolved in dry dimethyl sulfoxide (dried over 4 Å, 40 mesh molecular sieves) and 1 µL (500 µM final) was added to
the sample with thorough mixing. DSS is a chemical crosslinker that is directed toward
amino groups, thus facilitating the covalent incorporation of the peptides and proteins
used in this study (i.e., VEGF, NGF, laminins, and aprotinin) into the fibrin hydrogel
(196-200). The crosslinking reaction was incubated for 10 min at ambient temperature
in a humidified chamber. Thrombin (1 µL of 0.1 U/µL; Sigma-Aldrich) was added and
the sample quickly mixed and injected through a Gilson P20 Pipetman® into a quartz
tube (0.7 mm i.d., 3.5 cm long; Fiber Optic Center, Inc., New Bedford, MA) such that a 7
mm long cylinder was created. The dimensions of the final cylinder were 0.7 mm dia. X
6 mm long following the polymerization and concomitant shrinkage of the fibrin.
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Cylinders were made within 4h of implant surgery and stored in a humidified chamber
until used.

Implantation of cylinders into rat brain
Female Sprague-Dawley rats (175 g; 7 weeks old) were purchased from Hilltop Lab
Animals, Inc. (Scottdale, PA). Animals were acclimated and handled every 1–2 days for
2–3 weeks before experimentation. Cages were provided environmental enrichment in
the form of PVC pipe fittings. All animal experiments were carried out in accordance
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals
and performed under an approved protocol from Marshall University’s IACUC. The fibrin
cylinders were implanted along a predetermined path in the right hemisphere of each
animal (Fig. 1). A short (ca. 0.5mm) length of polyvinylidene difluoride (PVDF) fluorocarbon line (0.56 mm diameter leader material; Berkley, Columbia, SC) was inserted into
the quartz tube containing the fibrin cylinder and served as a plunger head and a 20 cm
length of stainless-steel wire (0.5mm dia.; AmazonSupply) was used as a plunger (Fig.
13). Animals were anesthetized using isoflurane (5% induction, 2% maintenance) with
an oxygen flow of 0.8 L/min.

49

50

Figure 13. Diagram of Coronal Section of Rat Brain Showing Location of Hydrogel Implant
The relative location of the cylinder is at an angle 17° right of midline, implanted
through the skull, relative to bregma, and at 0.13 cm anterior and 0.30 cm lateral
right of midline, with the distal end of the implant 0.73 cm dorsoventral to the skull.
The cylinder passes through the cortex, corpus callosum, the RMS, and into the striatum. The fibrin-based biomaterial degrades to completion after *4 weeks. Coronal
diagram reprinted with permission, originally published in ‘‘The Rat Brain in Stereotaxic Coordinates,’’ George Paxinos and Charles Watson, figure 13, Copyright Elsevier (1998). Inset: Implant assembly. A solution of fibrinogen/thrombin/immobilized
factors was injected into quartz tubes (0.7 mm i.d. · 35 mm length) such that 6 mm
long fibrin cylinders were produced. A plunger head made of PVDF was inserted
into the cylinder and pushed to the top of the fibrin cylinder using a 20 cm long stainless-steel wire (0.5 mm dia.) as a plunger. The plunger was removed and the quartz
tube/fibrin cylinder/plunger head assembly was affixed to the right arm of a stereotaxic frame and the plunger wire attached to the left arm. The fibrin cylinders were
surgically implanted into rat brains as described in the Materials and Methods section. PVDF, polyvinylidene difluoride; RMS, rostral migratory stream.
Animals were positioned into a Kopf stereotaxic frame that was outfitted with two
manipulators, one on each arm of the Kopf ‘‘U’’ frame, and both were angled 17° to the
right of midline. The fibrin cylinder-containing quartz tube was affixed to the right manipulator and the wire plunger was placed on the left manipulator. A small hole was drilled
using a round dental bur at, relative to the bregma, 0.13 cm anterior and 0.30 cm lateral
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right of midline (201). The dura was gently pricked with a 25-gauge needle and the
quartz tube slowly driven 0.73 cm down the dorsoventral axis on an angle 17° off midline to the right. The plunger was lowered into the fibrin cylinder-containing tube until
just touching the PVDF plunger head, which itself was just touching the fibrin cylinder.
The plunger was held immobile by the left manipulator arm, while the quartz tube was
slowly raised (1/4 turn/45 s) by the right manipulator. This maneuver resulted in the 6
mm cylindrical fibrin matrix being placed (not extruded) in the brain along a predetermined path (Fig. 13) as the quartz tube was removed from the brain with the plunger
holding the hydrogel cylinder in place.
The final position of the 6 mm long implant started at the surface of the brain and
passed through the cortex, corpus callosum, RMS, and striatum. After complete extraction of the quartz tube, the skull hole was plugged with bone wax and the scalp closed
with absorbable sutures. Animals were injected with dexamethasone [0.4 mg/kg subcutaneously (s.c.) in 0.9% sterile saline] once at the time of anesthesia induction and then
each day for 4 days postoperatively. For pain management, animals were injected with
buprenorphine (0.15 mg/kg s.c.) immediately after surgery and then daily for 2 additional days. Ten animals were used in this series; six received fibrin cylinders containing
VEGF, NGF, laminin I, and aprotinin; two were implanted with fibrin cylinders containing
only immobilized aprotinin and laminins, and two underwent sham surgeries (empty
quartz tubes driven to the same coordinates).
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6-hydroxydopamine lesions
Twelve rats were prepared for surgery as described above. The hemiparkinson
model was generated by 6-hydroxydopamine (6-OHDA) injections into the right medial
forebrain bundle (MFB). Desipramine was injected (i.p., 25 mg/ kg in sterile H2O) just
after anesthesia induction. The coordinates for MFB injection were, relative to bregma, 0.44 cm anterior; 0.12 cm right of midline; and -0.84 cm dorsoventral, and 3 mL of 6OHDA (5mg/mL in freshly made, degassed 0.9% NaCl/ 0.02% ascorbic acid) was injected at a rate on 0.5 mL/min. Following injection, the cannula was left in place for 5
min and then slowly removed (raised 1/4th of a turn every 45 s) and the site closed as
described above.
Two weeks postoperative, animals were injected s.c. with 5 mg/kg d-amphetamine in 0.9% NaCl and rotations were counted for 90 min in a Rotometer (San Diego Instruments, San Diego, CA). Out of the 12 6-OHDA-lesioned animals, 7 displayed
greater than 400 total ipsilateral turns and fewer than 5 total contralateral rotations and
were chosen for cylinder implantation as described above. Five animals received fibrin
cylinders containing VEGF, NGF, laminin I, and aprotinin, and two animals were implanted with fibrin/aprotinin/laminin as a control. Lesioned and subsequently implanted
animals were challenged with d-amphetamine 4 weeks following implant surgery to assess the impact of the cylinders on drug-induced ipsilateral rotations. Correction was reported as percent correction for each animal (number of turns before implant) - (number
of turns after implant) / (number of turns before implant).
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Immunohistochemistry
Animals were sacrificed 4–5 weeks following surgery, a point at which the cylinders were completely degraded, and we determined the phenotype and anatomical distribution of migrating neuroblasts in coronal sections of the brains. This time frame was
chosen to visualize Dcx+ cells utilizing a stable migratory path rather than merely responding to the inherent damage of the implant surgery, which should be resolved before the 4–5 week sacrifice time point (76).
Animals were sacrificed by bilateral pneumothoracotomy, fixed by transcardial
perfusion with 0.9% NaCl containing 2U/mL heparin followed by 4% freshly prepared
paraformaldehyde (PFA), and brains recovered. Following overnight postfixing in 4%
PFA, brains were equilibrated in 30% sucrose until no longer buoyant and stored at 4°C
until processed into 20 µm sections using a Leica Model 1950 cryostat. Samples were
incubated for 15 min in 50 mM NH4Cl, permeabilized in 0.1% Triton X-100, blocked
over-night at 4°C in 5% bovine serum albumin (BSA; Jackson Immunoresearch Laboratories, West Grove, PA) and 5% normal goat serum, and subsequently incubated with
primary antibodies (1:200 in 0.1% BSA-c™; Aurion (Wageningen, The Netherlands);
0.1% normal goat serum) overnight at 4°C. Sources of antibodies were as follows: Doublecortin (Dcx; a marker for immature neurons and neurogenesis), Millipore (Darmstadt,
Germany); Neurofilament medium (NF160; a marker for mature neurons), Abcam (Cambridge, MA); tyrosine hydroxylase (TH; a marker for mature dopaminergic neurons),
Abcam; microtubule-associated protein 2a and 2b (MAP2ab; a marker enriched in mature neuronal dendrites), Abcam; and glial fibrillary acidic protein (GFAP; a marker for
reactive astrocytes), Abcam. Following extensive washing, sections were incubated
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overnight at 4°C with Alexa-conjugated fluorescent secondary antibodies (Life Technologies, Carlsbad, CA) diluted 1:500. Following washing, samples were mounted on Superfrost plus glass slides (Fisher Scientific, Pittsburgh, PA) and coverslipped with number 1 glass with Fluoro-Gel II-DAPI (Electron Microscopy Sciences, Hatfield, PA) as the
mountant. Slides were sealed with clear nail polish and stored at 4°C until imaged/analyzed using a Zeiss Axio Observer with 10X and 20X LD Plan Neofluar air-interface objectives and AxioVision 4.6.3 software.

Results
Implanted fibrin cylinders recruit neuroblasts that migrate along the implant track
Immunohistochemical analyses of samples from animals implanted with fibrin cylinders containing NGF, VEGF, laminin I, and aprotinin revealed significant numbers of
migrating neuroblasts (Dcx+; Figs. 14 and 15). These cells exhibited complex, long, and
branching neurites and were most numerous along the original location of the cylinder in
the striatum. The new path facilitated by the hydrogel implant varied slightly in length
between animals and was between ~2.0 and 2.8 mm in length. Evaluation of the Dcx+
cells at higher magnification (Figs. 15 and 16) reveals the complexity of the neuroblasts’
neurites, many exceeding 100 µm in length and exhibit numerous branch points (Fig.
16). There was no residual mechanical damage due to the surgical procedure nor was
there significant GFAP+ labeling (data not shown) at the site of the implant, indicating
there was not a significant inflammatory response (202) to the matrix.
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Figure 14. Recruitment of Neural Precursors by the Fibrin Implant
Sections were labeled for migrating neuroblasts with anti-Dcx antibodies. Shown is a
whole coronal section revealing both the left (contralateral) nonimplanted and right
implanted hemispheres. Dcx+ cells (green) were observed in both hemispheres immediately dorsal to the lateral ventricles (indicative of the posterior RMS; signified by
the *), while only the implanted hemisphere exhibited significant Dcx+ cells in the striatum, along the implant path (indicated by the **). The length of the tract of neuroblasts in this animal is ~2.6 mm. The fibrin cylinder was itself degraded and the majority of labeling was along the track of the implant; additional labeling was observed
between the wall of the lateral ventricle and the implant track (Fig. 5). Dcx, doublecortin.
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Figure 15. Neuroblasts in the Implant Track Exhibit Complex Neural Morphology
To visualize the neural-like structures of the new cells in the implant region, a high
magnification image of the area was generated. Dcx+ cells (bright green) exhibit long
neurites along the implant path and many show complex branching, especially those
migrating toward and into the corpus callosum. The length of many of these neurites
exceeded 100 µm.
57

Figure 16. Higher Magnification of Neuroblasts and Neurites in the Implant
Region (from Fig 15)
Neuroblasts are prevalent along the implant region and their long neurites project parallel to the original, now degraded, cylinder. (a–c) Representative regions of the implant, dorsal (a) to ventral (c).

Additional Dcx+ cells were observed in implanted striatum in regions lateral to the
lateral ventricle, between the implant path and the ventricle wall (Fig. 17b), which were
not observed in the corresponding contralateral striatum (Fig. 17a). These new cells
may represent occult neural stem cells residing in the striatum that were stimulated to
differentiate due to the implanted microenvironment, or they may have arisen from the
lining of the ventricle and migrated directly toward the implant. We noted that many
Dcx+ cells in this intrastriatal region possess long (>100 µm) branched neurites with
morphology consistent with synaptogenesis (visible upon increased magnification),
which possibly suggests the beginning of functional integration of the new neural cells
into the existing circuitry (76, 203, 204).
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Figure 17. Additional Recruitment of Neuroblasts Between the Lateral Ventricle
and Implant Site
(a) Control nonimplanted left hemisphere. (b). Region comparable to that in (a), from
the implanted right hemisphere. Compared to the control hemisphere, this intrastriatal
region is rich in neuroblasts with complex morphologies. LV, lateral ventricle.
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The region of the striatum containing the highest density of new cells was a
clearly defined path from the RMS to the bottom of the cylindrical implant region in the
ventral striatum. It is of interest to note that, although the cylinder implant also led
through the cortex to the dorsal-most aspect of the brain, far fewer new cells were found
in the cortical region. Although neurites were clearly visible leading into the cortex, they
did not extend significantly into this region, despite being in the implant track (Figs. 14
and 15). Finally, the response of the endogenous SVZ-derived cells to the implant was
dependent upon the presence of neurogenic factors; no new neural cells, including dopaminergic (TH+) neurons, were observed in factor-free controls (Fig. 18), although
there does appear to be a disruption of the NF160-labeled ‘‘pencil tracts’’ (205) in the
implanted striatum (Fig. 18a).

60

Figure 18. Immunolabeled micrographs of Striatum for Each Treatment
Immunohistochemistry of striatal region of control implant, containing only fibrin, aprotinin, and laminin. (a) Section probed for NF160 cells (magenta). (b) Section probed
for Map2ab+ cells (red). (c) Section probed for tyrosine hydroxylase (green). (d)
Merged image from (a–c). Scale bar = 500 µm. Map2ab, microtubule-associated protein 2a and 2b.
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In vivo neural engineering corrects hemiparkinson rat rotational behavior
The robust neurogenic response to these brain implants suggested a therapeutic
application for this technology. We predicted that in an animal model of neurodegeneration, the fibrin cylinders would guide endogenous NPCs into damaged/dysfunctional
nonneurogenic regions; these cells would then functionally integrate and restore lost
function. We chose the 6-OHDA animal model of Parkinson’s disease since the anatomical location of the defect is well characterized (striatum, nigrostriatal pathway, and substantia nigra), the specific neural phenotype that is necessary for therapeutic efficacy is
readily assessed (labeling for TH), and correction of the behavioral deficiency is quantifiable (rotometer analysis).
Animals underwent unilateral 6-OHDA lesions to generate hemiparkinson rats
and subsequently were subjected to in vivo neural engineering by these novel implantable fibrin matrices. This experimental therapeutic approach appeared to correct the
asymmetric rotational defect in these animals (Fig. 19a). Immunohistochemical analyses of brains from corrected animals showed cells in the implanted striatum that were
decorated with antibodies against TH, suggesting a dopaminergic phenotype (Fig. 19b–
d). Control, lesioned animals implanted with fibrin cylinders containing only laminin and
aprotinin (and lacking NGF and VEGF) were not corrected by the procedure.
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Figure 19. Fibrin Implants Correct Amphetamine-Induced Ipsilateral Rotations in
Unilateral 6-OHDA- Lesioned Rats
(a) Shown are individual results from five lesioned animals that were implanted with fibrin
cylinders containing laminin, aprotinin, NGF, and VEGF. (b–d) Immunohistochemistry of
sections from implanted, corrected animals. (b) Section probed for tyrosine hydroxylase
(green). (c) Section probed for Map2ab (red). (d) Merged image showing nuclei (DAPI;
blue), tyrosine hydroxylase (green), and Map2ab (red). NGF, nerve growth factor; 6OHDA, 6- hydroxydopamine; VEGF, vascular endothelial growth factor.
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Discussion
Endogenous NPCs from the adult mammalian SVZ/RMS are an untapped source
of therapeutic neurons. The restorative potential of these adult neural stem cells can be
realized if a portion of the migrating neuroblasts can be steered away from their usual
destination (the OB) and into non- neurogenic regions of the brain where disease or injury has reduced the number of functional neurons. The long-term goal of our research
is to develop a means to retask these endogenous neural stem cells in the adult brain
by engineering new, relatively long migratory paths that lead these cells into nonneurogenic regions of the brain.
Our objectives were threefold; first, we engineered a biocompatible cylindrical
matrix that was of sufficient mechanical stability that it could be implanted into the brain
in a manner that essentially connected neurogenic to relatively distant nonneurogenic
regions. Other types of matrices that have been used to stimulate neurogenesis are relatively fluid and, while straightforward to inject, not likely to generate long engineered
pathways targeted to specific regions of the brain. Second, we used an aprotinin-stabilized formulation of fibrin for the implant because we posit that the ideal matrix must be
somewhat stable, yet biodegradable such that it will eventually yield newly developed
neural paths consisting of complex networks of neural cells and microvasculature. Our
data and others (150, 153) have demonstrated the ability of aprotinin, a peptide serine
protease inhibitor, to fine-tune the in vitro and in vivo neural cell-mediated degradation
rate of fibrin. This information was used in this work to generate a matrix that would be
completely degraded within 4–5 weeks. Third, we created an implantable biomaterial
with a cylindrical geometry that was readily modified with im- mobilized factors chosen
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to recruit endogenous NPCs from the SVZ-RMS and direct them into a typically nonneurogenic region. Since the quintessential neural migratory path in adult mammals is
the RMS, and this has a three-dimensional architecture that is relatively cylindrical, we
engineered fibrinogen, thrombin, and additional components as small implantable cylinders, cast in quartz tubes.
In this study we describe a biocompatible, biodegradable, modifiable, and implantable matrix, in the shape of a cylinder, which can be surgically placed in the brain such
that the implant connects the dorsoposterior RMS with the nonneurogenic striatum.
These implants were indeed capable of creating long tracts and enriched regions of new
neural cells in the striatum. Such in vivo brain tissue engineering has clear clinical applications for a variety of neurological disorders, especially considering that the source of
stem cells would be the patient’s own brain, without the need to implant any cells whatsoever. We believe that these deliberately targeted neurons will be repurposed from an
olfactory role to a new function specified by the nature of the neurological dysfunction
and the signaling cues within the milieu of the targeted niche (206-209).
Cell-replacement therapy in the brain has many hurdles that must be overcome and
the work described in this study addresses several of these challenges. Engineered fibrin cylinders can provide both the appropriate three-dimensional architecture and biochemically defined microenvironment to create a migratory path with complex neural
cells and vasculature. Upon implantation, this serves to recruit endogenous neural stem
cells from their usual location and subsequently target them into specific regions of the
brain. Harnessing endogenous adult neural stem cells eliminates the problems
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associated with exogenous cell transplants, which include deleterious immune responses and rejection, unavailability of sufficient numbers of cells for transplantation,
low survival and integration rates, and, in the case of embryonic or induced pluripotent
stem cells, teratoma formation.
We present three key findings in this report. First, as a result of the fibrin implant
containing neurotrophins (NGF and VEGF), ECM (laminin I), and protease inhibitor
(aprotinin) in normal rats, significant numbers of neuroblasts were found along an extensive (>2.5 mm long) region of the implant track in the striatum, in the striatal region between the implant track and the lateral ventricle, in the corpus callosum, and, to a much
lesser degree, in the cortex (Figs. 13-17). Fibrin alone was not sufficient to elicit this effect in terms of attracting neural cells into the implant region [compare control animals
(Fig. 18) to implanted animals (Figs. 14-17)] or correcting hemiparkinsonian behavior.
Only when VEGF and NGF were incorporated into the cylinders did we observe neuroblasts (Dcx+) along the track of the implant, which itself had essentially completely degraded. Second, there were no obvious deleterious neurological sequelae as a result of
the implants. We have not observed necrosis, tumors, reactive astrocytes (GFAP+), or
abnormal behavior in more than 80 animals that have been used during the development of this approach. Regarding inflammation, we attempted to minimize such cellular
responses (GFAP+ astrocytes) by the administration of an anti-inflammatory agent following the surgery; our unpublished preliminary studies show that GFAP labeling is induced by the surgical procedure and can be subsequently significantly reduced by postoperative dexamethasone administration. Third, 6-OHDA hemiparkinson rats exhibited
an attenuation of amphetamine-induced rotations following cylinder implantation (Fig.
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19). This provides proof of concept for the idea of creating a new neural migratory
stream that connects an abundant source of neural stem cells (the SVZ/RMS) to a dysfunctional brain region.
It is noteworthy to compare the morphology of the Dcx-reactive cells along the
implant tract (Fig. 16) with Dcx+ labeled cells along a bona fide migratory path. We observe Dcx+ neuroblasts with long neurites that run parallel to the direction of the implant. Such labeling and morphology are very similar to that observed for Dcx+ cells undergoing chain migration along the rodent RMS (210). It is reasonable to speculate that
the neuroblasts that respond to the fibrin implant are undergoing similar migration. The
fact that the animals were sacrificed 4 weeks after surgery and Dcx+ neuroblasts were
still present along the length of the implant track suggest that the new migratory path is
relatively stable over the postoperative time frame.
The likely source of new cells that were in abundance along the implant region is
the RMS, which the cylinder was designed to intersect after implantation. It is not clear
to us from where the cells that were seen in the striatal region between the implant and
the lateral ventricle are derived. We suggest that they may be either from the wall of the
lateral ventricle or are occult neural stem cells resident in the striatum that were activated by the implant. Regardless, in addition to the neural cells along the implant track,
the new cells in this intrastriatal region are likely to be therapeutically beneficial.
It is of interest to note that, compared to the robust generation of neuroblasts in
the striatal region of the implant, there were no nascent neural cells in the cortex. We
speculate that the brain itself provides additional signaling molecules that synergize with
the factors in the fibrin cylinder, and differential neurogenic responses are due to the
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biochemical cues inherent to the adult cortical environment versus those of the striatum.
Indeed, these different regions follow different neurogenic mechanisms during brain development (211-214) and this may account for the differential response (cortex vs. striatum) to the implanted fibrin microenvironment.
In conclusion, we present the development and therapeutic application in an animal model of neurodegeneration of an implantable, biocompatible, biodegradable fibrinbased cylinder, which can be readily modified with immobilized factors to create a bioengineered microenvironment that creates de novo neural migratory paths for in vivo
neural tissue engineering. Past efforts to accomplish similar goals have involved the injection of fibrin, usually with factors and exogenous stem cells, into regions of the brain
or spinal cord, which then polymerizes in situ (126, 191, 215, 216). It is difficult to envision the ability to create new, long migratory paths, which redirect endogenous neural
stem cells with such approaches. The safety of these implants remains to be characterized in detail, but we have not observed obvious behavioral problems, mortality, tumorlike masses, significant damage to brain tissue, or other gross abnormalities upon the
immunohistological analysis of the implanted brains.
Importantly, the main components of the implant described in this study are currently used in both routine and experimental clinical procedures. Fibrin (derived from fibrinogen and thrombin) and aprotinin (189) are common in many surgical procedures,
including neurosurgery. NGF, one of the two neurotrophic factors included in these fibrin
implants, has been delivered to patients’ brains in clinical trials for traumatic brain injury
and Alzheimer’s disease (217), while VEGF is being considered for stroke therapy (187,
218, 219). The recruitment of endogenous neural stem cells into regions of the brain
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that typically do not have neurogenic potential represents a powerful therapeutic approach for neurological diseases and disorders caused by the loss of specific neurons.
The ability to deliberately steer significant numbers of endogenous NPCs from their
usual niche into distant nonneurogenic regions of the brain represents a significant advancement for Parkinson’s disease, traumatic brain injury, stroke, and other neurological disorders of similar etiology.

Conclusion
Individuals with neurodegenerative disorders or brain injury have few treatment options and it has been proposed that endogenous adult neural stem cells can be harnessed to repopulate dysfunctional nonneurogenic regions of the brain. Here we presented hydrogel implants capable of recruiting endogenous cells from the adult subventricular zone to create new relatively long tracts of neuroblasts targeting them to a specific brain lesion. When these fibrin-based cylinders were implanted into hemiparkinson
rats, newly Dcx+ neuroblasts were found within the striatum of the implanted hemisphere and correction of parkinsonian behavior was observed.
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SECTION 3: BIOENGINEERING FIBRIN CYLINDER-IN-CYLINDER (CinC) BRAIN IMPLANT FOR STRIATAL AND COTRICAL NEURAL STEM CELL RECRUITMENT

Introduction
Neurodegenerative diseases, stroke, and TBI are notoriously difficult to treat due
to the brain’s limited capacity for regeneration. Once neural tissue is damaged patients
experience life-long, often debilitating, deficits. Stroke affects 800,000 people in America annually (220), but currently few treatment options exist for patients following a
stroke. To date, most stroke therapies are focused on either preventing further cell
death (221) or addressing symptomology due to this loss of neuronal cells (222), however, they do not address neuronal damage once it has occurred. Therefore, the development of new restorative therapies for stroke, and other causes of brain damage, that
focus on replacing lost or damaged cells, regenerating brain tissue, and recovering lost
function is a crucial next step in the treatment of neural injury.
The present work seeks to use the brain’s inherent neuroplasticity to replace
neurons lost to injury or disease by exploiting the migratory and regenerative capabilities of endogenous neural stem cells. Although the adult brain undergoes very minimal
neurogenesis, small niches of neural stem cells do exist and proliferate throughout the
life of mammalian animals. One such proliferative region is the subventricular zone
(SVZ). NPCs derived from the SVZ ordinarily travel relatively long distances along the
RMS to reach their destination in the OB. We hypothesize that these NPCs that traverse
the RMS can be redirected to other nonneurogenic areas of the brain if given an appropriate scaffold and chemotactic cues. Previously we have used an innovative
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bioengineered cell-free, implantable fibrin-based matrix capable of redirecting SVZ
NPCs from their normal course along the RMS. These fibrin implants create a sort of
“off-ramp” for the progenitor cells, thus establishing a new migratory stream in the brain
with the cells’ new destination in traditionally nonneurogenic regions. In a hemi-Parkinson rat model, the implantable matrix was able to recruit numerous neuroblasts to the
striatum leading to improved motor function (98). This preliminary data indicates that the
implantable matrix may be a useful tool for the recruitment of NPCs to areas of the brain
damaged from disease or injury.
However, the distance over which NPCs were recruited in our previous work was
limited. The implanted matrix spanned the entire length of cortex to midbrain, but newly
divided neuroblasts were primarily found along the implant site between RMS and striatum. We hypothesize these limitations can be circumvented with updates to the implant
architecture to a design that better promotes NPC migration and survival. NPC recruitment to cortical regions of the brain could prove useful in regenerative strategies following ischemic or traumatic brain injuries.
The physiological RMS structure is tubular, with glial cells extending parallel processes in opposite directions along the RMS to form a cord-like bundle, thus organizing
into an astrocytic glial tube (223). Chains of migrating neuroblasts traverse along the
RMS ensheathed by astrocytic processes and blood vessels to their destination in the
OB (224). Others have sought to recapitulate the RMS structure via fabrication of “living
scaffold” constructs composed of longitudinally aligned astrocytes (225) that shows
promise for endogenous NPC recruitment and neuronal cell replacement. However, this
approach requires complex microtissue engineering, has thus far been limited to in vitro
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experimentation (226), and poses possible complications related to the implantation of
foreign cellular material. Here we demonstrate our acellular, double-barreled “cylinderin-cylinder” (CinC) fibrin brain implants are capable of NPC recruitment to both striatal
and cortical ends of the implant tract.
The CinC is designed such that the inner fiber cylinder is softer and more rapidly
degraded than the outer fibrin cylinder (Fig 20), quickly creating a tube-like structure in
vivo. One advantage of the CinC unique architecture is that it allows for a wide variety of
possible ECMs and/or growth factors used to optimize cell recruitment. However, to
strictly evaluate the benefit of the double-barreled design, as compared to our previously homogenous cylinder implant, the same components are used as were in former
hemi-parkinsonism experiments in both inner and outer cylinder (98).

Figure 20. Schematic of Engineered CinC Matrix and Components
Depicted is an example of the double-barreled design for a “CinC” implant. Bottom
right reveals a plain photograph of a CinC’s gross appearance.
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Material and Methods
Preparation of implantable “CinC” scaffolds
Fibrinogen (Sigma-Aldrich, St. Louis, MO) was dissolved in phosphate-buffered saline (PBS) at a final concentration of 64 µM, degassed, and stored in aliquots at 80°C.
Eight µL aliquots of fibrinogen were placed on a square of Parafilm® to which was
added aprotinin (15 µM Sigma-Aldrich), laminin I (100 µg/mL Trevigen, Gaithersburg,
MD), carrier-free VEGF (10 µg/mL final concentration; R&D Systems, Minneapolis, MN),
and carrier-free NGF (10µg/mL final concentration; R&D Systems). The volume of each
sample was brought to 18 µL with PBS. The homobifunctional crosslinker disuccinimidyl
suberate (DSS; Thermo Scientific Pierce, Rockford, IL) was dissolved in dry dimethyl
sulfoxide (dried over 4 Å, 40 mesh molecular sieves) and 1 µL (500 µM final) was added
to the sample with thorough mixing. DSS is a chemical crosslinker that is directed toward amino groups, thus facilitating the covalent incorporation of the peptides and proteins used in this study (i.e., VEGF, NGF, laminins, and aprotinin) into the fibrin hydrogel (196-200). The crosslinking reaction was incubated for 10 min at ambient temperature in a humidified chamber. At this stage, two separate solutions have been prepared
for each the inner versus outer cylinders. To one aliquot, thrombin (1 µL of 0.1 U/µL;
Sigma-Aldrich) was added and the sample was quickly mixed and injected through a
Gilson P20 Pipetman® into the larger quartz tube (0.7 mm i.d., 3.5 cm long; Fiber Optic
Center, Inc., New Bedford, MA) with the solution surrounding the smaller quartz tube
(0.3 mm outer diameter [o.d.]; Fiber Optic Center, Inc., New Bedford, MA) such that a 6
mm long cylinder was created (Fig 21A). The dimensions of the final cylinder were 0.7
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mm dia. X 6 mm long following the polymerization and concomitant shrinkage of the fibrin.

A
B
C
D

Figure 21. Depiction of Cylinder-in-Cylinder Architecture
A) Fibrin solution is cast within larger quartz tubing and surrounding the smaller quartz
tubing. B) Once fibrin has hardened, smaller quartz tubing is removed to establish a
hollow tunnel through the casted fibrin. C) Fibrin solution for the “inner” cylinder in injected. D) The final result is a smaller hydrogel cylinder contained within a larger hydrogel cylinder, each of which may contain any variety of matrices and/or growth factors.
After fibrin was polymerized, the inner quartz cylinder was carefully removed
leaving a hollow tunnel within the fibrin inside of the larger quartz tubing (Fib 21B). To
the remaining fibrinogen aliquot, thrombin (1 µL of 0.1 U/µL; Sigma-Aldrich) was added
and the sample was quickly mixed and injected through a Gilson P20 Pipetman® into
the tunnel within the previously casted “outer” fibrin cylinder (Fib 21C). Therefore,
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creating the double-barreled design as depicted in Fig. 21D. Cylinders were made
within 4 h of implant surgery and stored in a humidified chamber until used.

Implantation of cylinders into rat brain
Female Sprague-Dawley rats (175 g; 7 weeks old) were purchased from Hilltop Lab
Animals, Inc. (Scottdale, PA). Animals were acclimated and handled every 1–2 days for
2–3 weeks before experimentation. Cages were provided environmental enrichment in
the form of PVC pipe fittings. All animal experiments were carried out in accordance
with the National Institutes of Health Guide for the Care and Use of Laboratory animals
and performed under an approved protocol from Marshall University’s IACUC. The fibrin
cylinders were implanted along a predetermined path in the right hemisphere of each
animal (Fig. 20). A short (ca. 0.5mm) length of polyvinylidene difluoride (PVDF) fluorocarbon line (0.56 mm diameter leader material; Berkley, Columbia, SC) was inserted
into the quartz tube containing the fibrin CinC and served as a plunger head and a 20
cm length of stainless steel wire (0.5mm dia.; AmazonSupply) was used as a plunger
(Fig. 20). Animals were anesthetized using isoflurane (5% induction, 2% maintenance)
with an oxygen flow of 0.8 L/min.
Animals were positioned into a Kopf stereotaxic frame that was outfitted with two
manipulators, one on each arm of the Kopf ‘‘U’’ frame, and both were angled 17° to the
right of midline. The fibrin cylinder-containing quartz tube was affixed to the right manipulator and the wire plunger was placed on the left manipulator. A small hole was drilled
using a round dental bur at, relative to the bregma, 0.13 cm anterior and 0.30 cm lateral
right of midline (201). The dura was gently pricked with a 25-gauge needle and the
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quartz tube slowly driven 0.73 cm down the dorsoventral axis on an angle 17° off midline to the right. The plunger was lowered into the fibrin cylinder-containing tube until
just touching the PVDF plunger head, which itself was just touching the fibrin cylinder.
The plunger was held immobile by the left manipulator arm, while the quartz tube was
slowly raised (1/4 turn/45 s) by the right manipulator. This maneuver resulted in the 6
mm cylindrical fibrin matrix being placed (not extruded) in the brain along a predetermined path (Fig. 20) as the quartz tube was removed from the brain with the plunger
holding the hydrogel cylinder in place.
The final position of the 6 mm long implant started at the surface of the brain and
passed through the cortex, corpus callosum, RMS, and striatum. After complete extraction of the quartz tube, the skull hole was plugged with bone wax and the scalp closed
with absorbable sutures. Animals were injected with dexamethasone [0.4 mg/kg subcutaneously (s.c.) in 0.9% sterile saline] once at the time of anesthesia induction and then
each day for 4 days postoperatively. For pain management, animals were injected with
buprenorphine (0.15 mg/kg s.c.) immediately after surgery and then daily for 2 additional days.
EdU (5-ethynyl-2’-deoxyuridine) labeling
To evaluate the ability of our CinC implant to recruit newly divided cells of the brain
along its entire course (cortex to deep brain nuclei), we implemented 5-ethynyl-2’-deoxyuridine (Edu) labeling. EdU, a nucleoside analog of thymidine that incorporates into
DNA during active DNA synthesis (227), was used to label any cell dividing cell at the
time of exposure. Beginning at week 12 following implant surgery, animals were injected
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with 50 mg/kg Edu i.p. every other day for 2 weeks. At week 14 after surgery animals
were sacrificed.

Brain extraction and imaging
Animals were sacrificed by bilateral pneumothoracotomy, fixed by transcardial perfusion with 0.9% NaCl containing 2U/mL heparin followed by 4% freshly prepared paraformaldehyde (PFA), and brains recovered. Following overnight postfixing in 4% PFA,
brains were equilibrated in 30% sucrose until no longer buoyant and stored at 4°C until
processed into 20 µm sections using a Leica Model 1950 cryostat. Samples were
mounted on Superfrost plus glass slides (Fisher Scientific, Pittsburgh, PA) and coverslipped with number 1 glass with Fluoro-Gel II-DAPI (Electron Microscopy Sciences,
Hatfield, PA) as the mountant. Slides were sealed with clear nail polish and stored at
4°C until imaged/analyzed using a Zeiss Axio Observer with 10X and 20X LD Plan
Neofluar air-interface objectives and AxioVision 4.6.3 software.

Preliminary Results
Edu+ cells were found bilaterally, as expected, along the lateral ventricles where
SVZ NSCs normally divide (Fig 22B). Numerous Edu+ cells were also discovered along
the implant tract (Fig 22A, C & D). The fibrin implant itself appears to have completely
degraded, which is consistent with prior studies (based on previous aprotinin dose response experiments, a fibrin cylinder containing 15 µM aprotinin would expect to be
largely degraded by 8 weeks), but in its place were newly replicated cells. Interestingly,
unlike the previously used homogenous, single cylinder, the CinC recruited young
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neural cells more distally towards the cortex (Fig 22D). On the contralateral, non-implanted hemisphere, Edu+ cells were seen adjacent to the lateral ventricle but few to no
Edu-labeled cells were observed elsewhere in the cerebrum. Over the period between
surgery and sacrifice, there were no obvious deleterious postoperative effects of the implants on the animals in terms of overt behavior, tumorigenesis or significant brain damage.
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Figure 22. EdU (5-ethynyl-2’-deoxyuridine) Labeled Brain Tissue from Rat Receiving Novel CinC Brain Implant 14 weeks Prior
A) coronal cross-section displaying Edu+ along the longitudinal axis of the fibrin implant
tract. B) magnified view of Edu-labeled cells within the SVZ/RMS. C-D) magnified views
of populations of Edu+ cells found along the healed implant tract.
*Of note, the dark circles with ring enhancement found throughout the sample are bubble artifacts within the mountant.
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Discussion
Many neuropathologies are sequelae of lost neurons due to toxic, ischemic, or mechanical injury. Therefore, many research efforts are focused on techniques to replace
these missing neuronal populations via SC transplantation (52, 228, 229), enhancing de
novo neurogenesis (230-233), or endogenous NSC/NPC recruitment (98, 111, 234).
Some success has been demonstrated with SC transplant or endogenous SC recruitment
in the striatum of rodent and primate models of PD (48, 49, 98, 164). Transplantation of
NSCs and/or mesenchymal SCs into the subdural space or ischemic lesions have also
demonstrated some success in functional recovery following stroke in both preclinical and
clinical models (51, 216, 235) (for a full review on the effectiveness of SC therapies in
stroke see (236)). However, the reliance on immunomodulatory agents following foreign
cell transplantation remains an obstacle.
Alternatively, others have focused their research efforts on better harnessing the intrinsic regenerative power of the brain. One approach has been to enhance the brain’s
innate “self-repair” mechanisms by attempting to increase the post-stroke upregulatory
response in neurogenesis and migration of neuronal precursors to ischemic lesions. Numerous cytokines and growth factors, administered systemically, by intraventricular injection or targeted delivery systems into stroke lesions, have been studied with variable success (90, 101, 103, 104, 109, 237, 238). Limitations for these approaches include offtarget effects throughout the body (108), inadequate number of progenitors reaching lesion to regenerate, lack of physical scaffold to support migration and/or growth of progenitors (111). This has motivated the application of various biomaterials in neuroregenerative research for both direct recruitment of NSC/NPCs to the area of damage and provide
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a physical scaffold to sustain migrating neuroblasts. Poor survival of recruited NPCs to
stroke lesions is frequently attributed to the lack of appropriate biological signaling, such
as lack of extracellular matrix or structural scaffold (239, 240) and inappropriate biochemical cues (241). Whereas an appropriately designed scaffold can provide these missing
components, thus offering a permissive environment for neuroblast migration and survival.
Using electrospun poly-ℇ-caprolactone (PCL) scaffolds containing either vehicle or a
BDNF-mimetic, Fon, et al. demonstrated that a physical scaffold is required to provide an
accommodating environment for neuroblast survival (111). Observing significant neuroblast infiltration into PCL implants at day 8 post-implantation, an effect seen regarldless
of incorporation of pro-migratory BDNF-mimetic. Although incorporation of a BDNF-like
molecule into their scaffold (PCL+mBNDF) did prolong the persistence of neuroblasts
rerouted along the implant tract (significantly more Dcx+ processes remained in
PCL+mBDNF than in PCL scaffolds at 21 days post implant) (111). They also revealed
direct intersection with the SVZ by a permissive scaffold is required to induce neuroblast
migration. As no neuroblast penetration was observed in PCL+mBDNF implants that did
not contact the SVZ, signifying the BDNF-like molecule itself was not sufficient to drive
NPC migration from SVZ/RMS to site of injury. When the implant contacted the SVZ,
neuroblasts were able to travel along the implant, however, the number of Dcx-immunoreactive cells within the scaffold decreased with increasing distance from the intersection
of the SVZ.
Feasibility of using scaffolds to re-route neuroblast migration from the SVZ or RMS to
targeted brain regions has also been demonstrated using implanted injectable gelatin-
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based hydrogels consisting of GDNF (124), graphene coated electrospun poly-ℇ-caprolactone (242), and most recently a new self-assembling peptide hydrogel (243). Unfortunately, the injectable hydrogel was degraded too quickly to promote NPC migration over
longer periods. The implant was found to be completely cleared after 3 weeks and the
number of neuroblasts around the gelatin matrix decreased from 7 to 21 days. It is unclear
however, if there were solely diminishing numbers of immature cells migrating along the
implant tract because of discontinued migration, or if the decrease in neuroblasts found
around the gelatin matrix tract was also due to differentiation of migrated neuroblasts to
neurons.
Another approach employed a hydrogel implant composed of exclusively ß-amino acids and a C14hydrophobic acyl tail with or without BDNF. The peptide self-assembles to
form a stable, long-lasting and biocompatible matrix (118). They evaluated biocompatibility, neuroblast migration, and cell differentiation at 7- and 35- days post-implant. Transgenic labeling of SVZ NSCs revealed an increase in cell migration in response to sham
(injury) at day 7 at appreciably lower numbers and distance of migrating cells than in the
plain or BDNF-loaded hydrogel. By day 35 migration was uniform across the BDNFloaded hydrogel with neuroblasts reaching the far end of the implant located in the cortex.
Most SVZ-derived cells along the hydrogels were Dcx+ at day 7, and the population of
these Dcx+ cells significantly decreased by day 35. At this time, most of the SVZ-derived
cells were colocalized with NeuN+, indicating the neuroblasts differentiated into mature
neurons. This differentiation trend was seen in both hydrogels, independent of BDNF.
These results found in the literature are important proof-of-principal that SVZ
NSC/NPCs can be re-routed from their normal course to desired brain regions, including
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the cortex. Further, recruited cells can differentiate into mature neurons in their new location. Of note, the authors of the aforementioned study speculate that providing stable,
long-term support will be essential for continued cell migration and differentiation. In contrast, we have hypothesized that once NPCs are effectively re-routed from the RMS, the
cells will continue to migrate as a neuronal chain analogous to their travel along the RMS
(244) forming a new, continuous migratory stream in the brain. We posit that the newly
established migratory route for SVZ NPCs will be replenishable and cells will continue to
travel the carved-out pathway long after the implanted matrix has degraded. Preliminary
evidence for this was demonstrated here. The fibrin-based cylinder-in-cylinders (CinC)
were implanted such that one terminal landed in striatal tissue and the other end reached
through the cortex ending at the most external surface of the brain, whilst intersecting the
RMS in the middle. Animals began receiving a 2-week series of Edu injections at week
12 post-implant. This would have been approximately 3-4 weeks, based on previous data,
after the fibrin implant itself had degraded. Therefore, Edu+ cells evident along the implant
tract must have been derived from an actively dividing population at the time of Edu injection after the implant matrix had degraded yet continued to migrate along the implant
tract.
One limitation of this study is that while continued cellular proliferation in the brain is
generally limited, at least in substantial amounts, to the SVZ and DG neurogenic niches
of the mature mammalian brain, certain inflammatory states also promote glial cell propagation (87). Additionally, it has been proposed that small quiescent SC niches throughout the brain may be activated in response to certain injuries, and thus could contribute
to Edu+ cells found along the CinC implant tract. As neither of these cell sources would
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likely provide a replenishable source of replacement cells for conditions such as PD or
stroke, the origin of Edu-labeled cells should be more definitively confirmed. To determine
if cells found along CinC implant tracts were derived from the SVZ, transgenic mice or
viral labeling techniques specifically labeling cell populations of the SVZ (245) should be
further investigated.

Conclusion
This study demonstrates proof-of-concept for NPC recruitment to non-neurogenic regions of the midbrain and cortex by an implantable matrix. Our “cylinder-in-cylinder” design proved to be more successful at allowing NPC migration to more distal locations
than its single, homogenous cylinder predecessor. Importantly, newly divided neural
cells were observed close to the gray-white junction of the cortex. A noteworthy finding
as our previous fibrin implants were found to only recruit Dcx-labeled NPCs to striatal
regions and the new migratory path ranged from only 2.0 to 2.8 mm in length from the
implant’s intersection with the RMS. The results of this study reveal the potential application of CinC fibrin implants in neuroregenerative research and an exciting new treatment paradigm for future studies.
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CHAPTER 3
CHAPTER INTRODUCTION
It has been postulated that nicotine may play a neuroprotective role in specific
neuronal populations (246-249), but may participate in other neurotoxic/neuroinflammatory pathways (250, 251). Moreover, if endogenous NSC/NPCs are to be exploited in regenerative therapies for disorders such as stroke, we must understand the possible implications a main risk factor for stroke, i.e. smoking, may have on these SCs. First, we
evaluate the modulation of α4 nicotinic acetylcholine receptor (nAChR) expression in
dopaminergic and gamma-aminobutyric (GABA) neurons of the ventral tegmental area
(VTA) following nicotine exposure via vapor inhalation in mice. Then we present a systematic literature review of nicotine’s effects on NSCs.
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SECTION 1: SYSTEMATIC REVIEW OF NICOTINE EXPOSURE’S EFFECTS ON
NEURAL STEM AND PROGENITOR CELLS

Introduction
Neurogenesis in the adult mammalian brain primarily occurs in two distinct regions: the SVZ located along the walls of the lateral ventricles and the SGZ located in
the DG of the hippocampus. NSCs reside and continue to symmetrically divide throughout adulthood in these regions giving rise to transiently amplifying multipotent NPCs (59,
61, 62). Neurogenesis in the DG plays a particularly important role in hippocampal-mediated learning (63, 64). In fact, enhanced neurogenesis and survival of newborn cells in
the hippocampus is observed in rats trained on hippocampal-dependent tasks (64), and
performance on these tasks is impaired by inhibition of cell proliferation (65). Newly
generated NPCs in the SVZ give rise to another type of neural precursor called the migrating neuroblast, which travel from the lateral ventricles to the OB along the RMS
where they then mature into neural cells involved in olfaction (60, 66-69, 252).
Because both clinical and preclinical studies have demonstrated that nicotine
elicits improvements in cognitive function (247, 253-258) and possibly offers neuroprotection against neurodegenerative conditions (259, 260), many studies have sought to
elucidate the effect of nicotine on neuroplasticity. In contrast to these studies driven by
the hypothesis that nicotine is a neuroprotective compound (261-263), others have
sought to evaluate nicotine’s effects on stem cells. This is due to evidence that nicotine
is a neuroteratogen and alters blood-brain barrier (BBB) function (264-266) and potentially contributes toward negative consequences for NSC health. Further, studies have
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shown abstinence from smoking in nicotine-dependent individuals leads to profound
cognitive impairment (267-269) and disruption of hippocampal and prefrontal cortex
(PFC) associated behaviors (270-274), suggesting that chronic nicotine exposure might
impair or otherwise alter mechanisms related to learning and memory such as hippocampal neurogenesis.
While the research of possible nicotine-related effects on NSC survival, proliferation and differentiation is understudied, investigation into this area has highly important
clinical implications. Although smoking rates have declined in recent decades, the 32nd
tobacco-related Surgeon General’s report states that 42 million American adults and
about 3 million middle and high school students continue to smoke. Additionally, nicotine use in the form of electronic nicotine delivery systems (ENDS) (also known as ecigarettes (Ecs)) has substantially gained popularity. Recent studies report that youth
who use ENDS may have a higher propensity to smoke combustible cigarettes in later
life (275). In 2019, over 5 million U.S. middle and high school students had reported
ENDS use in the past 30 days, including 10.5% of middle school students and 27.5% of
high school students (276). As brain development continues into the mid-twenties, elucidation of the neurological consequences of nicotine exposure is paramount (277, 278).

Nicotine-Related Decreases in NSC Proliferation
An in vitro study showed prolonged exposure to nicotine decreased proliferation
of NSCs isolated from embryonic whole brain (279) (Table 4). Brains collected from
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Observation

Nicotine Doses

Model Sys-

Ref

tem
(279)

Nicotine reduced the proliferation of

100, 400, 800

Neuro-

NSCs via transcriptional mecha-

µM

spheres

4 mg/kg/day

Mice

(280)

Variable

Rats

(281)

Nicotine decreases hippocampal

0.1, 0.5, or 1

Rats

(282)

neurogenesis

mg/kg

nisms
Nicotine reduced the NSC proliferation in the dentate gyrus (DG)
Nicotine reduced the NSC proliferation in the DG

Table 4. Summary of Nicotine-Related Decreases in Neural Stem Cell (NSC) Proliferation

embryonic day 16 mice were enzymatically treated to isolate NSCs and were cultured
as neurospheres. Neurospheres were then treated with vehicle or nicotine at 100, 400,
and 800 μM doses, concentrations that greatly exceed that of what is clinically relevant,
for five days. In a physiological setting, nicotine in the brain of combustible cigarette and
ENDS smokers is typically between 0.05 and 0.5 μM (283). The proliferative capacity of
nicotine treated NSCs was then analyzed via quantity and size measurements of the
cultured neurospheres. Nicotine decreased the number and size of newly formed neurospheres as compared to vehicle. Both diminished size and number were dose-dependent and could be restored by application of mecamylamine (MECA), a nonselective
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nAChR noncompetitive antagonist. Using RT-PCR to measure mRNA expression of
nestin, an NPC marker, and proliferating cell nuclear antigen (PCNA), it was shown that
nicotine inhibits proliferation of neurospheres at a transcriptional level. In the RT-PCR
analysis, the levels of nestin mRNA were not changed, whereas the level of PCNA was
significantly decreased. Additionally, confocal microscopy revealed nicotine treatment
increased the number of condensed nuclei and shortened neurogenesis in a dose-dependent manner compared to vehicle. Nicotine also increased the release of certain
pro-inflammatory cytokines in NSCs. RT-PCR analysis exposed increased levels of cyclooxygenase-2 (COX-2), tumor necrosis factor alpha (TNF-α), and glutathione reductase mRNA in the nicotine- treated neurosphere cultures. Intriguingly, variable TNF-mediated signal cascades in NSCs have been identified. Depending on which receptor
subtype is activated, NSC proliferation can be increased or decreased in response to
TNF-α (284, 285). Autocrine signaling of TNF-α is suggested to play a role in the cytokine’s influence on neurogenesis (285, 286). In addition to increased transcription of
these pro-inflammatory genes, nicotine was shown to increase the mRNA levels of histone deacetylase 1 (HDAC1) and decrease the mRNA levels of sirtuin 1 (SIRT 1, a nicotinamide adenine dinucleotide (NAD)-dependent histone and protein deacetylase) in
NSCs. HDAC2 was not changed with nicotine treatment. Nicotine also upregulated levels of inducible nitric oxide synthase (iNOS). When HDAC inhibitors, sodium butyrate
(NaB) or valproic acid (VPA), were added to NCS cultures for five days, HDAC1 mRNA
was decreased. However, neither NaB nor VPA changed mRNA levels of HDAC2 or
SIRT1. Furthermore, HDAC inhibitors partially rescued proliferation of NSCs compared
to nicotine without NaB or VPA.
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These results are interesting in light of other work that has reported chronic nicotine exposure to decrease HDAC activity in mice (287). Histone acetylation is an epigenetic modification to favor gene expression that is moderated by opposing actions of
histone acetyltransferase (HAT) and HDAC, adding and removing acetyl groups, respectively. Therefore, decreased HDAC activity would enhance histone acetylation and
promote gene expression. Commonly, activation of HDAC1 would result in transcriptional repression of many gene targets. In the aforementioned study, it is speculated
that HDAC1 might deacetylate a repressor bound to an iNOS promoter (288).
Epigenetic regulation has emerged in the literature as an important mechanism
underlying brain changes associated with nicotine and other drugs of abuse exposure.
In conjunction with the described study, others have demonstrated nicotine to decrease
SIRT1 levels in cultured mouse embryos (289). Sirtuins are a family of NAD-dependent
enzymes thought to be involved in cell metabolism and regulation of DNA repair, inflammatory response, cell cycle, and apoptosis (290). Interestingly, SIRT1, the sirtuin shown
to decrease following nicotine exposure, demonstrates a general neuroprotective effect.
In fact, hypermethylation of the SIRT1 gene and significant decrease of SIRT1 expression has been observed in patients with Alzheimer disease (291). Furthermore, epigenetic mechanisms were confirmed in vitro (292). These and other nicotine-induced epigenetic changes could be responsible for the negative effects of nicotine on NSC proliferation.
Nicotine impairment of neural plasticity has also been observed in multiple in vivo
studies (280, 282, 293). Abrous et al., found that nicotine self-administration greatly decreased expression of polysialylated (PSA) forms of neural cell adhesion molecule
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(NCAM) in the DG in a dose-dependent manner (293). They also observed nicotine-related decreases in neurogenesis and increased cell death (Figure 23). Using male Sprague Dawley rats and an intravenous self-administration (IVSA) model, animals self-administer one of three unitary doses of nicotine (0.02, 0.04, and 0.08 mg/kg per infusion)
or vehicle solution, delivered on a contingent basis. Following IVSA, brain sections were
collected and analyzed for PSA-NCAM and Brdu (Bromodeoxyuridine/5-bromo-2′-deoxyridine) immunoreactivity. PSA-NCAM was evaluated because in the adult hippocampus PSA-NCAM is expressed in newborn neurons (294) and in mutant mice, modifications of PSA-NCAM expression causes morphological changes to these hippocampal
cells and worsens cognitive function (281). PSA-NCAM immunoreactive cells were located in the deepest region of the granule cell layer at the interface of the hilus within
the hippocampus. Nicotine IVSA diminished PSA-NCAM expression in the DG, a decrease up to 44% less than control in the 0.04 mg/kg nicotine dose (Figure 23). Notably,
the PSA-NCAM expression was unaltered in the SVZ of nicotine-treated rats. Immunoreactivity for Brdu was decreased in the DG of rats that received nicotine IVSA compared to those receiving vehicle. Again, Brdu-labeling was not altered with nicotine
IVSA in the SVZ. Both changes in PSA-NCAM immunoreactivity and Brdu-labeling were
most significantly modified by the medium (0.04 mg/kg) dose of nicotine. Evaluation of
either neuronal cell marker, NeuN, or astrocytic marker, GFAP, were co-labeled with
Brdu to reveal the phenotype of proliferating cells. In control animals, approximately 7%
of Brdu-stained cells expressed astroglial marker GFAP, and about 60% of Brdu-stained
cells were NeuN-positive. In nicotine IVSA rats, the percentage of Brdu-stained cells colabeled with GFAP or NeuN was not significantly different than the percentages of that
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Figure 23. Graphical Summary of Nicotine’s Effects on NSC Proliferation
Nicotine exhibits region-specific effects on neurogenesis. In the subventricular
zone (SVZ), nicotine exposure enhances specific effects on neurogenesis. In the
subventricular zone (SVZ), nicotine exposure enhances neurogenesis while in the
SGZ it decreases neurogenesis. neurogenesis while in the SGZ it decreases neurogenesis.
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in control animals. While the total number of Brdu/GFAP-positive cells was also not
changed by nicotine administration, the total number of Brdu/NeuN- positive cells was
decreased in a dose-dependent manner. The medium dose of nicotine (0.04 mg/kg) had
the least amount of Brdu-stained NeuN-positive cells, equaling about half the amount as
the Brud/NeuN-positive cells in control. Nicotine IVSA also resulted in greater cell death
within the granule cell layer of the DG, demonstrating a significantly increased number
of pyknotic cells with dose-dependent nicotine exposure in this region. Again, the greatest number of pyknotic cells within the DG was actually seen in the medium dose of nicotine, with both 0.04 and 0.08 mg/kg nicotine doses resulting in heightened cell death
as compared to control or lower dose (0.02 mg/kg) nicotine.
In response to the seemingly controversial work of Abrous et al., as their study
appeared inconsistent with prior work that had reported cognitive-enhancing properties
of nicotine (255, 256, 295-297), Scerri et al., sought to investigate the effects of constantly infused nicotine on rat spatial learning in the Morris water maze and cell proliferation in the DG (280). In this study, two doses of nicotine were chosen, the high dose (4
mg/kg daily) representing blood nicotine concentrations (approximately 80 ng/mL) found
in heavy smokers and the lower dose (0.25 mg/kg daily) to approximate concentrations
(approximately 8 ng/mL) commonly found in the plasma of light smokers. They found
that only the high dose nicotine (HDN) animals, and not the low dose nicotine (LDN) animals, took longer than controls to find the platform. Moreover, in probe trial, only HDN
rats spent significantly less time than control rats in the region where the platform had
been located. The group difference was not attributed to changes in swim speed. In all
groups (HDN, LDN and control), spatial learning increased the number of Brdu+ cells in
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the DG as compared to rats not receiving the learning task. Administration of HDN reduced the number of Brdu+ cells in both trained and non-trained rats. Further, HDN, but
not LDN, decreased the number of cells labelled with BrdU compared to controls.
One other study observed nicotine-related decreases in hippocampal neurogenesis (282). Interestingly, Shingo et al. had shown in a prior study that nicotine administration in rats increased mRNA expression of insulin-like growth factor 1 (IGF1) within the
hippocampus and cerebral cortex. Here, the authors concluded that this was partially responsible for nicotine’s beneficial effects on hippocampal and cortical neurons (298). In
their later study, nicotine was injected intraperitoneally (i.p.) (doses 0.1, 0.5, or 1 mg/kg)
into adult male Wistar rats for two weeks and immunohistochemistry was performed on
hippocampal tissue slices to label PSA-NCAM, NeuN, and GFAP (282). The quantity of
PSA-NCAM+ and NeuN+ cells were decreased greatly by nicotine (Figure 23). While
the actual count of immunolabeled cells was not provided, the values expressed as percent of control revealed a dose-dependent decrease of PSA-NCAM- and NeuN-labelled
cells in the DG with nicotine exposure (Figure 23). The highest dose of nicotine used (1
mg/kg) had a nearly 80% decrease in both PSA-NCAM+ and NeuN+ cells, while the
percentage of control for GFAP-labelling was unchanged. Although the 0.5 mg/kg nicotine dose alone did reach a statistically significant increase in GFAP-labelling, the increase was not as great a percentage change as that found in PSA-NCAM or NeuN labeling, and the authors thus reported nicotine has no effects on the number of GFAP+
cells. Moreover, Shingo et al., suggest that nicotine may have a “two-sided effect” on
neurons, having a positive effect on mature neurons and a negative effect on developing neurons (Figure 23).
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Nicotine-Related Increases in NSC Proliferation
In contrast to studies mentioned above that have demonstrated either decreased
neural precursor cells number within the hippocampus or no change in NSC number
within the SVZ, Mudò et al. reported that acute intermittent nicotine treatment enhanced
neural precursor proliferation in the SVZ (299) (Table 5). Adult male Wistar rats were
administered a total of four injections given i.p. every 30 min at a dose of 1 mg/kg for
the acute intermittent nicotine treatment group and similarly treated with saline for the
control group. To evaluate the effect of nicotine on precursor cell proliferation, i.p. injections of BrdU 2 h before sacrifice were also used to label proliferating cells. Changes in
neural precursor cell proliferation were measured at 24, 36, 48, and 72 h after acute intermittent nicotine treatments. The time-course study revealed a significant enhancement of SVZ precursor cell proliferation as seen by an increased number of Brdu+ cells
in the SVZ of nicotine treated rats versus controls at 36 h after nicotine exposure and
maintained at least 72 h after (299). Nicotine did not induce neural precursor proliferation in the SGZ of the adult hippocampus. The enhanced SVZ neural precursor proliferation is thought to be caused by a nicotine-induced increase in fibroblast growth factor 2
(FGF-2) mRNA in the SVZ (Figure 23). Using in situ hybridization for both FGF-2 and
fibroblast growth factor receptor 1 (FGFR-1) mRNA in the SVZ, they found that 4 h after
acute intermittent nicotine treatment FGF-2 mRNA was upregulated in the SVZ while
FGFR-1 mRNA was not. Additionally, the use of a specific monoclonal antibody against
FGF-2 administered into the lateral ventricles 24 h after nicotine treatment, blocked the
enhancing effects of nicotine on SVZ neural precursor cell proliferation.
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Nicotine
Observation

Model System

Ref

Rats

(299)

Rats

(300)

Doses
Intermittent nicotine exposure
increases neural precursor
1 mg/kg
proliferation in the SVZ due to
increases in FGF-2
Nicotine dependence and
deprivation increases the
number of immature neurons

Variable,
IVSA

in the SGZ of the DG
Table 5. Summary of Nicotine-Related Increases in NSC Proliferation
Administration of a FGFR-1 inhibitor, SU5402, into the lateral ventricles 24 h after
nicotine treatment also inhibited nicotine-induced effects on precursor cell proliferation
(299). Moreover, a significant reduction of precursor cell proliferation was observed
when SU5402 was intraventricularly injected in control rats as well, suggesting a role for
endogenous FGF-2 in normal adult SVZ neurogenesis. In order to verify that augmentation of SVZ neural precursor cell proliferation by acute nicotine treatment was mediated
by activation of nicotinic receptors, pre-treatment with nonselective nAChR antagonist
MECA was injected 30 min prior to acute intermittent nicotine treatments. MECA pretreatment did counteract the enhancing effects of acute intermittent nicotine on precursor cell proliferation. Further, treatment with MECA alone did not alter precursor cell
proliferation in the SVZ compared to control animals (299).
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Mudò et al., (299) also sought to identify cell types expressing FGF-2 and FGFR1 in the SVZ as well as determine nicotine’s effect on precursor cell differentiation. Double-labelling of FGF-2 or FGFR-1 in combination with nestin revealed that along the
SVZ ventricular epithelium only FGFR-1 was co-expressed with nestin. This suggests
that SVZ precursor cells may respond to FGF-2 produced and released by other neural
cell types present in and around the SVZ (Figure 23). Double-labelling of FGF-2 with
GFAP demonstrated that in the SVZ FGF-2 is expressed in cells also expressing GFAP.
Because both astrocytic cells and NSCs within the SVZ are GFAP-positive (as they advance down the neural lineage, NPCs and neural precursors no longer produce GFAP),
they examined if Brdu+ cells were also GFAP or nestin-positive. Brdu-labeled cells were
GFAP-negative, indicating nicotine-induced enhancement of proliferation in the SVZ
was not targeting SCs. On the other hand, all Brdu+ cells were nestin+ cells, signifying
that actively proliferating cells are likely the target for nicotine’s proliferative effects (Figure 24). These results suggest that nicotine induces release of FGF-2 from GFAP+ cells
that target FGFR-1 on nestin+ actively proliferating cells (299).
Lastly in this investigation, rats were treated with acute intermittent nicotine or saline and after 24 h received i.p. Brdu. Rats were sacrificed 12 days following nicotine
treatment (299). This resulted in all Brdu-labelled cells residing in the OB with few in the
RMS and none in the SVZ. Using NeuN- and GFAP-labelling and co-localization with
Brdu, no nicotine effects on differentiation of SVZ NPCs were detected. All Brdu+ cells
that had migrated to the OB were NeuN+ in both saline and nicotine treated groups, and
no co-localization of Brdu and GFAP were observed in either treatment group. Remarkably, in all experiments performed, the nicotine enhancement of precursor cell
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proliferation was not accompanied by an increase in number of apoptotic cells, as
shown by comparable TUNEL-labelling in every experimental and control group. Therefore, this study indicates nicotine is not involved in mechanisms underlying fate specification of SVZ neural precursor cells nor does it influence neural precursor cell or their
progeny’s survival (299).
In another study that reported a nicotine-induced increase in neurogenesis, Cohen et al., (300) demonstrated nicotine dependence and deprivation increases levels of
immature neurons in the SGZ of the DG. Here, the authors also observed that nicotine
positively correlates with the number of immature neurons in the hippocampus following
extended nicotine access in rats. Male Wistar rats received jugular catheter implants for
nicotine IVSA or did not undergo intravenous surgery to serve as controls (control animals did not receive saline/vehicle implants). Nicotine infusion were contingent upon
nose-poke of active lever in nicotine IVSA group. A periodic deprivation model was
used, in which weekly nicotine self-administration was available for either extended access (21 h per day) or limited access (1 h per day) for 4 d, followed by 3 d of abstinence. Nicotine self-administration continued under this model for 14 weeks and then
brains were immunohistochemically analyzed. Proliferation marker, Ki-67, and immature
neuron marker, neurogenic differentiation factor (NeuroD; transiently expressed in differentiating progenitors between day 1 and 7 after cell birth (301)), were not altered by
limited access nicotine self-administration. While extended access nicotine self-administration and deprivation led to significantly higher numbers of Ki-67-labelled cells and
NeuroD immunoreactive cells in the SGZ as compared to naïve controls (300). A significant increase in NeuroD+ cells was observed in the SGZ of extended access rats in
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both pre-deprivation and post-deprivation stages as compared to controls and limited
access rats. Neither limited nor extended access nicotine self-administration and deprivation was shown to induce apoptosis, as the number of activated caspase 3 labelled
cells was not altered in these groups compared to naïve animals. Additionally, gliogenesis in the medial prefrontal cortex (mPFC) was evaluated and neither nicotine self-administration groups showed a difference in the number of proliferating progenitors and
premyelinating oligodendrocytes. Limited- and extended-access nicotine self-administration did not alter Ki-67-labelling in the mPFC and did not change the number of Oligo2 labeled premyelinating oligodendrocytes in the mPFC compared to control animals
(300).
Cohen et al., (300) revealed that in limited access rats, no significant correlation
was observed between number of NeuroD+ cells and number of nicotine lever presses
following depravation of nicotine. Alternatively, there was a strong correlation between
number of NeuroD-immunoreactive immature neurons and the number of nicotine lever
presses post-deprivation during the last week of self-administration in the extended access rats. Consequently, nicotine dependence may have negative effects on the hippocampus leading to aberrant hippocampal neurogenesis. Abnormal proliferation within
the SGZ may contribute to maladaptive addiction-like behaviors that are dependent on
the hippocampus. This study corroborates clinical studies that have demonstrated that
nicotine-dependent individuals show pronounced impairments in hippocampal-associated behaviors such as learning and memory following abstinence from smoking (272274, 302-305).
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Nicotine Attenuates Aß-Induced Neurotoxicity in NSCs
Evidence supports nAChRs’ role in the differentiation, maturation, survival and
integration of newly born neurons in the adult brain (306-308). Immature neurons derived from ongoing neurogenesis within the DG contain α7 nAChRs and receive direct
cholinergic innervation that is critical for integration of these adult-born neurons into the
DG network (306). Nicotine has demonstrated neuroprotective abilities upon bind- ing
nAChRs on numerous cells throughout the brain, acting therapeutically by inducing defense mechanisms against pathology causing Alzheimer’s disease (AD) (309, 310), Parkinson’s disease (PD) (259, 311-315) and other neuroinflammatory conditions. Nicotine’s actions on hippocampal α7 nAChRs has been shown to prevent synaptic impairment induced by Aß oligomers through activation of phosphatidylinositol-3-kinase
(PI3K) signaling pathways (316) (Table 6). Through its action on astrocytic α7 nAChRs
and subsequent PI3K/Akt signaling transduction, nicotine protected against Aß aggregation by modulating levels of endogenous astrocytic αB-Crystallin (317). Nicotine has
been shown to protect against neuroinflammation that plays a causative role in post-operative cognitive dysfunction (POCD) (318). Nicotine mitigated POCD in partially hepatectomized rats by reducing inflammatory cytokine expression and activating brain-derived neurotrophic factor/tropomyosin receptor kinase B (BDNF/TrkB) signaling, thus
preventing neuronal apoptosis in the hippocampi of these animals (262). Nicotine also
regulates inflammation via α7 nAChRs on microglia and activating intracellular signaling
cascades that ultimately inhibit the production of proinflammatory factors like TNF-α, interleukin (IL)-1 and reactive oxygen species (ROS) (for review on α7 nAChRs immune
modulation see (319)). However, less is known about nicotine’s contributions, directly or
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indirectly, to NSC fate against neurotoxic compounds involved in such neurodegenerative and/or neuroinflammatory states.
Nicotine

Model Sys-

Doses

tem

Observation

Ref
Cultured hip-

Nicotine prevents Aß aggre-

10 µM (culpocampal

gation via hippocampal α7

tures),

(316)

neurons,
nAChRs

1 mg/kg (mice)
mice

Nicotine is neuroprotective by
reducing inflammation by acti0.5 mg/kg

Rats

(318)

vating BDNF/TrkB and inhibiting TNF- α and IL-1
Nicotine-induced activation of
α7 nAChRs attenuates Aß-induced neurotoxicity by reduc-

Cultured hip1 µM

ing Aß accumulation in mito-

pocampal

(320)

NSCs

chondria
Table 6. Nicotine-Related Neuroprotection and Neurotoxicity in NSCs

Two in vitro studies sought to assess the impact of nicotine on Aß-induced neurotoxicity on NSCs through nicotine’s effect upon binding microglial α7 nAChRs (266,
320). The rationale being that following deposition and accumulation of Aß, a secondary
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phenomenon of inflammation contributes to the loss of cholinergic neurons characteristic in AD pathophysiology (321). It is also known that Aß interacts with nicotinic receptors (322, 323) and stimulating nAChRs increases Aß internalization and prevents aggregation (213, 324). Additionally, microglia play an important role in regulation of neurogenesis (325). Taken together, cholinergic drugs may promote recovery in AD, at
least partially, by restoring NSC populations, as activated nAChRs can improve the microenvironment of the brain by preventing production of microglia-derived inflammatory
factors and increasing Aß phagocytosis.
The aim of the first study was just that, to improve the survival microenvironment
of NSCs co-cultured with microglia by attenuating microglia-derived inflammatory factors mediated by Aß peptide accumulation (266). To evaluate this, Jiang et al., (266)
used four experimental groups: (1) a control group in which NSCs were cultured with no
interventions; (2) Aß-treated group in which NSCs were exposed to 10 μmol/L of Aß142; (3) co-cultured group in which NSCs were cultured in a transwell system with microglia which had been treated with 10 μmol/L of Aß1- 42; and (4) a nicotine pretreated
group in which microglia were pretreated with 10 μmol/L nicotine for 1 h before being
treated with 10 μmol/L of Aß1- 42 and subsequently co-cultured. They found that low
concentration nicotine de- creased release of pro-inflammatory cytokines stimulated by
Aß in primary microglia. Levels of TNF-α and IL-1 were significantly elevated in the microglia co-culture group versus the NSC-only control group, and these levels were decreased when treated with nicotine (10 μmol/L). Proliferative rates of NSCs were shown
to be lower in the Aß-treated group and even greatly diminished in the co-cultured
group. Nicotine pretreatment was able to partially rescue NSC proliferative rates.

102

Immunoreactivity for microtubule-associated protein 2 (MAP2), a neuronal marker particularly enriched in the dendrites (326), and choline acetyltransferase (CHAT), used to
label cholinergic synapses (327), revealed nicotine mitigates changes in NSC differentiation provoked by microglia-derived factors induced by Aß. The control group contained
14.6% MAP2+ cells and 4.0% CHAT+ cells. While the Aß-treated group had 10.2%
MAP2+ cells and 3.0% CHAT+ cells, and the co-cultured group had 5.6% MAP2+ and
0.9% CHAT+ cells. The nicotine pretreatment group was observed to have partially restored to a condition that resembled cultures without microglia present (8.3% MAP2+
cells and 2.1% CHAT+ cells). Using Annexin V/PI staining and TUNEL assays, the
apoptosis rate of each condition was determined. Again, the greatest effect of Aß was
seen in the presence of microglia, with the percent of apoptotic cells out of total cell
population increasing from less than 10% in control to 41.3% in co-culture group. The
effect of nicotine on NSC apoptosis also demonstrated the same trend as other series in
this study. The apoptosis rate decreased to 29.7% but was still greater than control or
Aß groups that did not contain microglia. Lastly, the authors examined the Wnt/ßcatenin pathway as the mechanism underlying the observed neuroprotective effects of
nicotine. The results demonstrated Axin2 played a negative role in the Wnt/ß-catenin
pathway in NSCs co-cultured with Aß-treated microglia. Nicotine enhanced Wnt/ßcatenin signaling by upregulating ß-catenin, phosphorylating glycogen synthase kinase
3ß (p-GSk-3ß), and downregulating Axin2 and phosphorylated ß-catenin. Altogether this
partially ameliorates the microglia-activated inflammatory response in NSCs. These
data suggest the Aß may have some direct negative consequences on NSC
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proliferation, differentiation, and survival. However, Aß toxicity is primarily mediated
through microglial actions.

Figure 24. Summary of Described Effects of Nicotine E-Cigarettes (EC) Liquid
and Aerosols on NSC Mitochondria
EC treatments led to altered mitochondrial membrane potential (MMP), induced aggregation of mitochondrial nucleoids and mitochondrial DNA, and induced calcium influx
leading to plasma membrane retraction and intracellular calcium overload.
The second study also used a transwell system to evaluate the indirect cytotoxicity of Aß-mediated microglial activation on NSCs (320). Because many of the microglia-derived proinflammatory factors have been shown to induce neuron death often
through mitochondrial dysfunction (328-332), Chen et al. sought to uncover the
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mechanism interconnecting mitochondrial function and inflammation-mediated NSC
death and how nicotine might therapeutically intervene through its actions on microglial
nAChRs. In addition to evidence that the mitochondria is a primary target in inflammation-mediated neural cell death, it has also been shown that Aß progressively accumulates in the mitochondria of cells throughout the brain (333). They found that blocking
the mitochondrial permeability transition pore (mPTP) (which plays a central role in
apoptotic neuronal death (334)) and activating the α7 nAChRs on microglia attenuated
Aß-induced neurotoxicity on NSCs (Figure 24).
Interestingly, Chen et al., (320) did not detect α7 nAChR immunoreactivity on
NSCs. This finding is in opposition to previous work that reported α7-nAChRs are present on undifferentiated stem cells and progenitor cells throughout the body (335). Still
yet, others have shown the importance of α7 nAChRs present on hippocampal NPCs
and immature neurons on differentiation, maturation, integration, and survival (306,
336). An exact expression pattern for nAChRs on NSCs and their progeny has not yet
been clearly established. Although it appears nAChRs are vital for certain stages of
neurogenesis, in this study α7 nAChR subunit mRNA was only detected on primary microglia, while no detectable expression of α7 nAChR subunit in primary NSCs was observed.
The results of this study (320) showed blocking the mPTP in NSCs or activating
the α7 nAChR in microglia rescued NSC mitochondrial activity. The NSC mitochondrial
membrane potential (MMP) and morphological characteristics were respectively measured by JC-1 staining and transmission electron microscopy. The addition of Aß-treated
microglia more significantly altered mitochondrial depolarization in NSCs than the
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addition of Aß directly to NSC culture without microglia present. When Aß-treated activated microglia were pretreated with 1 μM nicotine, their negative effects on NSC mitochondria were partially reversed. The altered NSC mitochondrial membrane permeability was also partially corrected when NSCs were treated with cyclosporine A (CsA),
which targets cyclophilin D, an essential regulator of the mPTP opening (337), and ultimately blocked the mPTP. Nicotine or CsA pretreatment was also shown to reverse Aßinduced mitochondrial cristae swelling. Lastly, Aß-mediated microglial activation greatly
increased the apoptotic rate of NSCs compared to control. Nicotine activation of microglial α7 nAChRs and blocking of the mPTPs by CsA attenuated the observed NSC
apoptosis.

Nicotine Induces Mitochondrial Stress in Neural Stem Cells
Changes to SC mitochondrial health could have highly important implications as
mitochondria play a key role in regulating stemness (71, 338-343). Recently, in addition
to preventing senescence, mitochondria have also been linked to stem cell activation
and determining fate/differentiation (342-344). Unfortunately, mitochondria are also sensitive to stress (345), leaving them susceptible to possible damage from nicotine and/or
other toxic byproducts from tobacco use. Moreover, a decline in SC mitochondria function could underlie accelerated aging traditionally seen in smokers.
Studies have suggested nicotine exposure affects the mitochondrial respiratory
chain, oxidative stress, calcium homeostasis, mitochondrial membrane proteins, mitochondrial as- sociation from microtubules, mitochondrial dynamics, biogenesis, and mitophagy (346, 347) (for full review on nicotine’s impact on mitochondrial activity see
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(348)). However, few studies have specifically examined the impact of nicotine exposure on NSCs and their mitochondria. As discussed in the previous section (Nicotine attenuates Aß-induced neurotoxicity in NSCs), Chen et al., demonstrated a link between
NSC mitochondrial function and Aß-induced neurotoxicity. Interestingly, the results of
that study advocate for a protective role of nicotine against microglia-derived proinflammatory factors that have been shown to induce neuron death via mitochondrial dysfunction (Figure 24). In a transwell coculture system, Aß-mediated microglial activation led
to mitochondrial dysfunction within NSCs and caused NSC apoptosis. These negative
effects were attenuated by treatment of microglia with 1 μM nicotine and treatment of
neurospheres with a mitochondrial permeability transition pore inhibitor. This suggests
that mitochondria may play a critical role in nicotine’s action as a neuroprotective agent
for NSCs.
In contrast, Zahedi et al., demonstrated a mitochondrial stress response in NSCs
following exposure to electronic cigarette ENDS e-liquids and their aerosols (349). Importantly, they also reported that the effects of ENDS on the mitochondria are mediated
by nicotine and not by the transfer of volatile organic chemicals or solvents found in eliquids (propylene glycol and glycerin). Cultured NSCs were incubated for 4 or 24 h with
menthol- or tobacco-flavored e-liquids (0.3%, 0.5% and 1% dilutions) or aerosols (1, 3,
and 6 total-puff-equivalents (TPE)). The results of this study revealed that EC liquids
and aerosols inhibit proper autophagy in NSCs. Autophagosomes were enlarged in a
time-dependent manner, with a greater enlargement seen in e-liquid exposed than aerosol exposed cells. The enlarged autophagosomes also demonstrated an increase in pH.
(Figure 24). The decrease in autolysosome acidity could decrease its normal proteolytic
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function. This is important as mitophagy, or mitochondrial autophagy, protects cells by
removing damaged mitochondria which could induce pro-apoptotic signaling. After 4
and 24 h e-liquid and aerosol treatments mitophagy had not significantly increased, except in the high-dose 1% menthol-flavored nicotine e-liquid group. Using time-lapse imaging and a motion-magnification algorithm they did observe e-liquids and aerosols alter
mitochondrial dynamics. Treatment with both e-liquids decreased large motion and increased small motion as compared to controls. While menthol-flavored aerosol decreased small motion and increased large motion of NSC mitochondria, and the same
trend was observed in tobacco-flavored aerosol treatment but was not statistically significant when compared to control.
The changes observed in mitochondrial dynamics appear to correlate with alterations in mitochondrial swelling or hyperfusion (Figure 24). Greater motion was seen in
hyper- fused mitochondria (aerosol) and less motion was seen in the swollen mitochondria (e-liquids). As hyperfusion has been shown to increase superoxide production
(350), they loaded cells with a mitochondrial-targeted dye that produces fluorescence in
the presence of superoxide anion. A dose-dependent escalation of fluorescent intensity
was observed in e-liquid-treated cells, and a lesser increase also found in the aerosoltreated cells. Using immunoblot analysis, it was determined that cells treated with e-liquid or aerosol also had significantly elevated superoxide dismutase two levels compared to controls. Additionally, a concentration-dependent increase in mitochondrial protein oxidation was observed in all e-liquid and aerosol treatments.
This study also provided evidence that EC e-liquids and aerosols can cause significant and not-easily-reversible damage to the mitochondria of NSCs. EC treatments
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led to altered MMP, induced aggregation of mitochondrial nucleoids (Figure 24) and mitochondrial DNA (mtDNA), and induced calcium influx (Figure 24) leading to plasma
membrane retraction and intracellular calcium overload. Labelling with tetramethylrhodamine methyl ester (TMRM) dye, a cell-permeable, cationic dye that is sequestered by
active mitochondria but leaks out of depolarized mitochondria, revealed changes in
MMP in NSCs treated with high-dose e-liquid or aerosol for 24 h. Treatment with aerosols (hyperfused mitochondria) increased TMRM accumulation in the mitochondria.
While 1% liquid (swollen mitochondria) had different results. The 1% tobacco-flavored
nicotine e-liquid showed no change in TMRM, and the 1% menthol-flavored nicotine eliquid dose showed a decrease in TMRM signal, suggesting this concentration damages
the mitochondria and causes membrane leakage. Because an elevation of ROS can
lead to mtDNA damage, a dye was used to label mitochondrial nucleoids. Control cells
had multiple small fluorescent nucleoids, whereas e-liquid (0.5%) and aerosol (6TPE)
for 24 h treated cells had larger, brighter nucleoids characteristic of mtDNA aggregation.
Lastly, EC- and nicotine-induced alterations to calcium influx were evaluated.
NSCs transfected with a fluorescently tagged calcium reporter (GcaMP5) and imaged
live before and after exposure to e-liquid (0.5% menthol- or tobacco-flavored), aerosols
(6TPE menthol- or tobacco-flavored), and various concentrations of nicotine (220 μg/mL
or 1.1 μg/mL). An increase in intensity was seen at one minute for all conditions and
was most pronounced in 0.5% menthol-flavored nicotine e-liquid and 220 μg/mL nicotine solution. These data also showed that calcium levels did not return to baseline by
20 min after exposure, resulting in calcium overload. Much of the fluorescent signal was
seen accumulating in the perinuclear region, which was presumed to be due to
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sequestering of calcium by the endoplasmic reticulum. However, because intracellular
calcium can also accumulate in the mitochondria which can then trigger ROS production
(351), NSCs were then transfected with a genetically encoded calcium indicator called
calcium-measuring organelle-entrapped protein indicator (CEPIA). Transfected cells
were again imaged live before and after exposure to e-liquid (0.5% menthol- or tobaccoflavored), aerosols (6TPE menthol- or tobacco-flavored), and various concentrations of
nicotine (220 μg/mL or 1.1 μg/mL). All treatments showed an increase in fluorescent
signal within 1 min, followed by a decrease by 44 min. Again, the greatest changes
were observed 0.5% menthol-flavored nicotine e-liquid and 220 μg/mL nicotine. Unlike
the other treatment, the calcium levels in these groups did not return to resting state by
20 min following exposure. NSCs were then pre-incubated with Ru360, a compound to
block calcium uptake through mitochondrial calcium uniporter (MCU) proteins. With calcium uptake through MCU inhibited, the changes in intracellular calcium following e-liquid, aerosol, or nicotine exposure were significantly dampened. Mitochondrial calcium
influx was also successfully inhibited by blocking α7 nAChRs with α-bungarotoxin (α7
nAChR competitive antagonist). Lastly, they sought to evaluate if calcium blockage
could impede mitochondrial effects of Ecs and nicotine. Thus, NSCs were incubated
with 1 μM calcium chelator EGTA (ethylene glycol-bis(ß-aminoethyl ether)- N,N,N’,N’tetraacetic acid) and treated with 0.5% e-liquids for 4 h. The results showed a significant
decrease in mitochondrial superoxide production when EGTA was present. The authors
conclude these data suggest calcium overload contributes to EC-induced mitochondrial
defects in NSCs.
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Discussion
Adult neurogenesis plays an important role in learning and memory (352), olfaction (252), and the brain’s ability to regenerate after injury (353). Albeit limited, the brain
does have some capacity to self-heal following insults such as stroke. Ischemic and
traumatic lesions within the cortex have been shown to stimulate proliferation in the SVZ
(70-72, 175, 354). These newly born neural cells then migrate along blood vessels (355)
to the site of injury to where they differentiate primarily into glial cells and fewer become
mature neurons (70, 74, 354). One physiological limitation is a substantial lack of integration of these recruited endogenous precursor cells, particularly in the case of stroke
as ischemia creates a very hostile microenvironment for the newly arriving cells (74).
Since the revelation that neural precursors can migrate to sites of injury within the brain,
considerable research efforts have been placed on creating a more robust neurogenic
response, promoting NPC migration, and enhancing integrative capacity into damaged
regions following stroke and other neurodegenerative conditions (98, 101, 230-232,
356, 357). As this field of regenerative research advances, it will be important to understand what effects the main risk factors for stroke, such as smoking, have on the health
of NSCs.
In addition to effects nicotine may have on continued postnatal neurogenesis and
its implications for the possible exploitation of NSCs therapeutically in adults, it is also
important to consider nicotine-induced changes in prenatal neurogenesis. While the
scope of this review primarily focuses on SCs and progenitors of adult neurogenesis, it
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is important to note that ENDSs are often used by adolescents and pregnant women.
During development, SCs of the nervous system are especially vulnerable to toxicants
(358). In attempts to abandon smoking, pregnant women may resort to the use of nicotine patches or ENDSs that are colloquially considered less dangerous (359). These
methods nevertheless introduce nicotine, which is considered a neurotoxic and neuroteratogenic agent (360-363), to the developing fetus. Notably, evaluation of maternal
nicotine exposure during gestation and lactation period in mice revealed alterations in
neurogenesis in offspring (364). Nicotine-exposed offspring were found to have altered
behavior, increased cell proliferation in the DG, more disorganized immature doublecortin positive (Dcx+) neurons, and increased microglial markers.
The mRNA for neuronal nicotinic receptor subunits and nicotine receptor binding
sites are first detected at the end of neurulation, and at that point the developing brain
becomes vulnerable to nicotine exposure (365, 366). Importantly, this process occurs
early in pregnancy as primary neurulation begins week 3 of gestation (367). Newly born
cells destined for neuronal lineage migrate from the mitotic zone to various regions of
the developing brain then nAChR expression becomes regionally specific (368, 369). As
previously mentioned, nAChRs play a role in differentiation, maturation, integration, and
survival of newly born neurons throughout adulthood (306-308). In the fetal brain acetylcholine signaling is important for coordinating proper assembly of the neural tissues
(370). Maternal cigarette smoking has been associated with structural and functional alterations within the brain, including in the mPFC (371), striatum, amygdala, and hippocampus (372), and numerous cognitive and behavioral changes (373, 374), such as
deficits in learning and memory (375), auditory dysfunction (363), hyperactivity (376),

112

and depressive-like behaviors (377), in the offspring (for a full review of pre-clinical and
clinical evidence of nicotine’s effects on development in the nervous system and more
see (378)).

Conclusions
The current state of research on nicotine’s effects on neural stem, progenitor and
precursor cells is still in its infancy and there is much to be discovered. Presently nicotine appears to have differential effects on these immature cells of neural lineage depending on both location and maturation. Nicotine may exert a protective role for NSCs
when exposed to cytotoxic or inflammatory agents. The mitochondria of NSCs appear to
also play an important role in these interactions between NSCs, glia, and nicotine. Additionally, nicotine may have differing effects on NSCs depending on route of administration and further research is needed to determine these consequences.
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SECTION 2: EXPRESSION OF ALPHA4 NICOTINIC ACETYLCHOLINE RECEPTOR
SUBUNITS ON DOPAMINERGIC AND GABAERGIC NEURONS OF THE VENTRAL
TEGMENTAL AREA FOLLOWING PASSIVE INHALATION VAPORIZED NICOTINE
IN MICE

Introduction
Ventral Tegmental Area and Parkinson’s Disease
Parkinson’s disease is a neurodegenerative disorder predominantly affecting dopaminergic neurons for which there is no cure (10). While the motor symptoms of PD are
generally more familiar to the general public, non-motor symptoms ranging from mild cognitive impairment to severe dementia also occur frequently in PD (379). Just as tremor,
bradykinesia, rigidity, facial masking and gait instability progressive over years, cognitive
deficits also tend to worsen with disease duration (379, 380). It is important that we uncover and understand the neural networks involved in both motor and cognitive parkinsonian symptoms for more comprehensive treatment of PD patients.
It is thought that selective dopaminergic degeneration within the ventral mesodiencephalon leaves the dopamine (DA) neurons of the VTA partially spared while the
DA neurons of the substantia nigra pars compacta (SNc) are much more significantly
degenerated in PD (381, 382). While the VTA is more resistant to DA neuron degradation in PD, it does experience about a 50% neuron loss (383, 384). This leads to loss of
DA input to the ventral striatum which may cause or contribute to the cognitive decline
seen in PD patients, as these connections are important for learned associations, incentive salience and memory consolidation in the brain (385-387).
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Further, both SNc and VTA have overlapping projection patterns. The SNc DA
neurons are understood to be mainly involved in circuits controlling motor movements
while the VTA DA neurons are primarily responsible for regulation of reward, emotional
behavior and addiction (388). The majority of SNc neurons project to dorsal striatum
and only some nigral fibers project to the ventral striatum and the cortex and, conversely, the VTA sends most projections to the ventral striatum and cortex with fewer
going to the dorsal striatum (388, 389). Moreover, both SNc and VTA DA neurons send
minor projections to additional brain regions including the globus pallidus, subthalamic
nuclei, and habenula (388, 389). Ultimately, the SNc and VTA work together to play a
key role in modulating motor behavior through the basal ganglia (390). As such, pathology of the VTA may play a significant role in the motor and/or non-motor symptoms of
PD and modulation of this region may prove therapeutically beneficial.

Nicotine and Nicotinic Receptors in the Brain
Several retrospective and prospective population-based epidemiological studies
have shown an inverse correlation between patient history of tobacco use and development of PD (249, 391-395). Since 1959, numerous studies have demonstrated this trend
in the clinical setting, revealing an approximately twofold decrease in PD risk with tobacco
use (396-399). The inverse correlation between smoking and PD has also been shown
to be dose-dependent, with a decreased incidence observed with both increased smoking
intensity, or number of cigarettes smoked per day, and with number of smoking years
(391, 392, 395, 400, 401). Therefore, interrogation of nicotine as a neuroprotective agent
and elucidation of possible underlying neuroprotective mechanisms is important. While
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causal mechanisms are not fully understood, several studies have observed nicotine-associated neuroprotective effects in in vivo models of Parkinsonism (311, 312, 402-404).
However, others have suggested that chronic nicotine does not directly protect against
degeneration, but rather modifies DA receptor dynamics (405, 406), still others propose
nicotine both plays a role in degenerative prevention and alters activity at DA synapses
to maintain or restore normal function with nigrostriatal damage (407).
Of interest to the present research, is evidence that the decline of α4 nAChR subunits is much less compared to other nAChR subtype expression in the striatum of parkinsonian animals (408). Suggesting α4 nAChRs may be more resistant to PD-related
striatal DA neuron degradation and may prove a potential target to ameliorate PD motor
symptoms. Additionally, other research has shown pharmacological chaperoning by nicotine upregulate α4ß2 nAChRs in the plasma membrane of neurons with chronic nicotine
exposure (409). Here we expanded upon evidence that long-term nicotine exposure upregulates α4ß2 nAChRs in the brain. Specifically, we have implemented a passive vape
inhalation paradigm in which α4ß2 nAChR upregulation has not previously been described. With ENDS usage gaining popularity as an alternative to traditional combustible
cigarette smoking, alterations in neural nAChRs following ENDS exposure is highly important.

Material and Methods
Reagents
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Free-base nicotine (product number – N2472-100ML, lot number – 2AH0278) was
obtained from Spectrum. 30% Propylene Glycol and 70% Vegetable glycerin (30/70
PGVG) was obtained from La Jolla Alcohol Research, Inc. (La Jolla, CA).

Mice
All experiments were conducted in accordance with the guidelines for care and
use of animals provided by the National Institutes of Health. Protocols were approved by
the Institutional Animal Care and Use Committee at Marshall University. Mice were kept
on a standard 12/12 h light/dark cycle at 22 °C and given food and water ad libitum.
Knock-in α4-mCherry mice originating from a C57/BL/6J background were utilized in all
experiments. The creation of the α4-mCherry knock-in mice has been previously reported
(410, 411) and maintained at Marshall University Animal Care Facility. Postnatal day 21
mice were weaned and housed with same-sex littermates. For genotyping, tail biopsies
were acquired between postnatal day 16–21 for PCR analysis, using previously published
methods (412) by Transnetyx (Cordova, TN). Only mice that were homozygous for α4mCherry were selected for use in e-Vape inhalation and confocal assays. For all experiments, both male and female adult (3 - 5 months old) mice were used.

Passive e-liquid vapor inhalation assays
Passive vapor delivery was conducted in four air-tight chambers with interior dimensions of 35 cm L x 25 cm W x 22 cm H (La Jolla Alcohol Research, Inc. La Jolla, CA,
USA). The chambers were housed in a dark Plexiglas enclosure that minimized extraneous light and noise. Airflow was vacuum controlled by an electric pump that allowed air
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flow at 1 L/min. The air outlet was located at the top back corner of the right wall of the
camber and connected through tubing to a HEPA-Cap filter (product number – 26091, lot
number - 3953048) from Midland Scientific. The vapor port was located in the front of the
chamber and the e-liquid solutions were contained in a SMOK® baby beast TFV8 X-baby
Q2 atomizer tank (0.40 ohms dual coil; Shenzhen IVPS Technology Co., Ltd., Shenzhen,
China) that was activated by a custom e-cigarette mod box (La Jolla Alcohol Research,
Inc., La Jolla, CA, USA). Vapor delivery settings were controlled by an e-Vape custom
controller (La Jolla Alcohol Research, Inc., La Jolla, CA, USA, www.ljari.tech).
Three- to five-month-old α4-mCherry mice were placed, separating male and female, into passive inhalation chambers for three-hour sessions for a total of 10 days.
Sessions ran 5 days consecutively with a 2-day (weekend) abstinence in between. This
was done to match the exposure paradigm of e-Vape self-administration assays (413).
Time-triggered puffs of e-liquid vapor were performed the same for nicotine and control
groups and were as follows: 3-sec puffs administered directly into the passive chambers
every 3 min for 3 days, every 2 min for 3 days, and every 1:20 min for 4 days. This escalation of the vapor deliveries within the 3 hr sessions is modeled after the average fixedratio 1 escalation of mice in the first 10 sessions of e-Vape self-administration. The nicotine group received puffs of vaporized e-liquid containing 12 mg nicotine. Once 3 hr sessions were completed mice were returned directly to home cages.

Confocal imaging of mouse brain slices
Labeling was derived from direct α4-mCherry excitation and emission in α4mCherry mice. Additionally, immunohistochemistry was performed for tyrosine
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hydroxylase to differentiate dopaminergic and GABAergic neurons. Following the completion of the final passive vape inhalation assay, mice were euthanized with CO2 and
subjected to rapid cardiac perfusion with ~10 mL cold saline. This clearance of blood from
the cerebrovasculature has been previously shown to significantly reduce the autofluorescence in the mCherry emission range (412). The whole brain was then carefully dissected from the cranium, frozen immediately, and stored at −80 °C. Brains were coronally
sectioned (20 μm thickness) using a Leica CM 1950 cryostat, mounted with Vectashield
(Vector labs, H-1000), and coverslipped. Bregma range -3.1 mm to -3.3 was collected
(only slices containing VTA were imaged in this study, however, we also sought to capture
SNr and SNc for storage and future evaluation). A Leica SP5 TCSII confocal microscope
was used to excite α4-mCherry at 561 nm. Imaging was performed at 20X magnification
with a 5X digital zoom.

Imaging and statistical analysis
A Leica SP5 TCSII confocal microscope was used for imaging of the α4-mCherry
and Tyrosine Hydroxylase (TH) stained mouse brain slices. TH and α4-mCherry were
excited at 488 and 561 nm, respectively; 10× images with a 5× digital zoom were collected for the quantitative measurements.
Quantitative measurements of α4-mCherry neuron fluorescence intensity were
done using ImageJ. The raw integrated density (RID) and mean were recorded from ImageJ analysis and used for the measurements of fluorescence for each neuron. A minimum of 20 VTA neurons were analyzed per mouse. Data for both parameters were averaged for each mouse.
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Statistical analyses were performed using Graphpad Prism. Males and females
were analyzed separately. Potential sex differences were analyzed using a two-way
ANOVA and posthoc Bonferroni for the comparison of means.

Results
The current data yield no statistically significant differences between male or female nicotine of PGVG vehicle treatments (Fig 25). However, a non-statistically significant
increase in α4 nAChR expression was observed in female, but not male, mice following
passive nicotine vapor inhalation as compared to controls. Future studies are needed to
elucidate if such a difference exists.
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Figure 25. Dopaminergic and GABAergic α4nAChR Expression in VTA
α4-mCherry mice were exposed to vaporized PGVG alone or PGVG containing 12 mg
nicotine in passive inhalation chambers for three-hour sessions for a total of 10 days.
A) Raw integrated density (RID) values for VTA dopaminergic neurons in males and females following nicotine exposure and vehicle controls. B) Raw integrated density
(RID) values for VTA GABAergic neurons in males and females following nicotine exposure and vehicle controls. All data points (average RID for each mouse) are shown
±SD; *p<0.05; Ordinary Two-way ANOVA.
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Discussion
Limitations of this study include a low number of mice included and therefore possibly underpowered data. If the difference in means for female versus male mice passively exposed to vaporized nicotine is truly similar to that presented here, then a power
calculation reveals a minimum of 6 subjects per treatment group should be used in future studies. However, we suspect that the greatest drawback of our methodology was
the use of larger vape chambers than what has been previously used in our lab. We
later found cotinine levels to be lower than expected in mice placed in these particular
chambers as compared to previous experiments using smaller vape chambers (data not
shown).
Motor symptoms of PD are classically attributed to the death of substantia nigra DA
cells and subsequent loss of dopamine signaling within neural circuits essential for proper
motor control. Several authors postulate that DA cell death is, at least in part, the result
of alterations in the actions of the proapoptotic effector, C/EBP homologous protein
(CHOP) (414-418). Activation of CHOP occurs in DA cells as a result of Ca+ influx and
potentially toxic byproducts of dopamine metabolism that these cells are subjected to
which then affect proteostasis (419-421). Proteins involved in the unfolded protein response (UPR), which under normal cellular conditions are responsible for detecting unfolded and misfolded proteins, display sustained activity in DA neurons consequent of
these pathophysiologic stressors (416). Unmitigated UPR subsequently activates CHOP,
leading to propagation of apoptosis signaling in DA neurons. It is therefore unsurprising
that prolonged ER stress and persistent UPR have been implicated in PD pathogenesis
(422).
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One proposed neuroprotective mechanism of nicotine is through suppression of
endoplasmic reticulum (ER) stress and the UPR (423). It has been shown that chronic
nicotine exposure leads to nAChR upregulation through intracellular pharmacological
chaperoning, but it is only one of several consequences of pharmacological chaperoning by nicotine (409). Nicotinic ligands permeate through cell membranes and exert
other pharmacological chaperoning effects including modifications on ER stress and the
UPR (409), which was further studied in a cultured model for nicotinic neuroprotection
(410). One study found that in cultured ventral midbrain DA neurons given smoking-relevant dose for 2 weeks (200 nM nicotine from 7 to 21 d in culture) pretreatment with nicotine prevents CHOP activation following DA neuron exposure to known ER stress inducer, Tunicamycin (50 or 150 nM for 72 hr). Nicotine’s protective effect, however, was
limited as only partial suppression of CHOP elevation was noted at the higher concentration. Additionally, they demonstrated mecamylamine (MECA), a broad spectrum nAChR blocker, failed to suppress this effect further supporting evidence that nicotine does
not just exert effects following plasma membrane binding, but also acts as an intracellular chaperoning role. Suppressed activity in three arms of the UPR triggered by ER-resident stress sensors, XBP1, ATF6, and protein kinase RNA-like ER kinase (PERK) pathway, by chronic nicotine was also observed. Another important finding of this study was
that nAChRs are required for nicotine-induced reduction in ER stress markers, shown
by using transfected neuroblastoma cells. Results that are supported by their previous
work revealing low-dose nicotine acts as a pharmacological chaperone of NAChRs in
the ER, which then suppresses ER stress and UPR (423). Importantly, another indicator
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of pharmacological chaperoning by nicotine is the upregulation of α4ß2 nAChRs in the
plasma membrane of neurons with chronic nicotine exposure (409).
Accruing evidence indicates that nicotine and nAChR ligands may influence PD
motor symptoms by two different mechanisms: 1) protection against nigrostriatal damage, and 2) nAChR ligands may directly stimulate the DA system to acutely ameliorate
motor-related symptoms. Targeting α4-containing nAChRs may prove useful for these
effects as nigrostriatal damage in PD has been shown to lead to a much lesser decline
in certain α4 nAChRs compared to other nAChR subtype expression in the striatum
(408). Quick and Wonnacott (399) outline the differential impact on nAChR expression
in the striatum in parkinsonian animals following damage to the nigrostriatal DA pathway. Briefly, all α6-containing nAChRs in the striatum were dramatically diminished following nigrostriatal damage, while α4ß2 nAChRs present on striatal DA terminals were
more mildly declined. Additionally, no decline was observed for α4ß2*, which are not
found on striatal DA terminals, or α7 nAChRs. Therefore, α4ß2 nAChRs preserved on
other elements, not DA neurons, may contribute to local nAChR-mediated effects in the
striatum.
More research is needed to further define nAChR expression patterns in the dorsal versus ventral striatum. As noted previously, multiple dopaminergic networks are affected to varying degrees in PD leading to different motor and non-motor signs and
symptoms. It appears α4-containing neurons and DA neurons of the VTA are more resistant to the cytotoxic pathology in PD. These neurons may prove useful if targeted appropriately in overcoming certain movement and/or cognitive problems PD patients
face.
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Conclusion
At this time no conclusions can be drawn about the effects of passive vaporized
nicotine exposure in mice on α4 nAChR expression on DA or GABAergic neurons within
the VTA. More studies are needed to elucidate if this manner of nicotine delivery does
or does not alter α4 nAChR expression.
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GENERAL DISCUSSION
Here we have discussed multiple facets of current and potential therapies for different neurological conditions with a focus on PD and stroke. PD is the second most
common neurodegenerative disease in the world and as it currently stands, is uncurable
(10). The current standard of care for advanced PD, and other movement disorders, inadequately controlled by pharmacological means is DBS placement (18). We found that
while the majority of U.S. surgeons currently split up DBS system implant into multiple
surgeries, it is a safe and effective under skilled hands option to perform the entire
placement in a single operative session. It has been feared that increased time under
anesthesia and longer incision-to-closure time would result in increased length of stay,
greater infection rates, and other postoperative complications. However, we found in a
single institution study that this was not the case. A single-staged DBS implantation
proved non-inferior regarding negative outcomes in a 90-day post-op period. This is important as many of our patients travel long distances from rural locations or have other
limitations to transportation. Performing their DBS surgery not only decreases trips to
the OR for these patients but also cuts back on pre-and post-op travel to and from the
hospital.
Secondly, a novel technique of creating new neural tracts using fibrin-based
brain implants for neuroregeneration was discussed. We demonstrated that fibrin can
be made predictably stable in neural environments through the incorporation of protease inhibitor aprotinin. Further, a simple and inexpensive method for immobilizing aprotinin in hydrogel implants was described using a chemical crosslinking agent. While
every other component found in our fibrin implants has been studied or is currently
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being used in clinical application, DSS has not. Future work is needed to evaluate the
safety of DSS and/or other chemical crosslinking agents for human use before this
method could be translatable.
Thus far, these engineered fibrin implants have been shown effective at recruiting progenitor cells to the striatum and partially improving motor dysfunction in a hemiparkinson rat model. Further, an updated implant architecture was developed, transforming the homogenous, solid fibrin cylinder to a double-barreled, cylinder inside a cylinder design. The CinC is intended to recapitulate the tubular structure of the anatomical
RMS (223) and thus better promote SVZ NPC migration. Another advantage of the renovated design is that it allows a great combination of possible matrices and factors that
can be incorporated into the implants. As many different cytokines and growth factors
have been shown to improve NPC migration, differentiation, and maturation, this structure allows for an assortment of factors to be evaluated. In the future, studies are
needed to evaluate these chemotactic and growth factor combinations to determine
those optimal for cell differentiation and migration. Additionally, work is needed to determine how effectively recruited NPCs can integrate and function in their new environment.
Next, α4 nAChR expression on DA and GABA neurons in the VTA of mice passively
exposed to vaporized nicotine was assessed. In the literature, it has been shown that
following chronic nicotine exposure, the high-affinity α4ß2 nAChR subtype widely upregulates in the brain (424-426). A trend we expected but did not clearly see here. Further,
sex differences are beginning to be reported for drug-induced nAChR expression in various brain regions as well as for nicotine behaviors (427-431). These reports suggest that
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it may be beneficial to further explore our nonsignificant findings of nicotine-induced increased α4 nAChR expression on DA neurons of the VTA in female mice only.
While nicotine was discussed in the context of its possible neuroprotective actions on
DA cells, nicotine does not reinstate function once nigrostriatal damage has already occurred, its actions are primarily protective in nature not restorative (248, 249). One study
showed when a 2- to 3-week nicotine regimen was administered to rats before nigrostriatal lesioning, improved dopamine transporter levels in the striatum were observed (432).
Conversely, when the same dose and time intervals of nicotine were administered to rats
after lesioning, no change in transporter levels was evident compared to animals not receiving nicotine. Thus, there remains a need for neuroregenerative therapies for striatal
(and other brain regions) damage, such as the bioengineered brain implants presented
here. Bringing us to the final subject matter discussed, nicotine’s potential effects on
NSCs.
If endogenous NSC/NPCs are to be used for regenerative purposes in PD or stroke,
then we must understand what implications nicotine poses on the health and function of
those cells as smoking is thought to be neuroprotective for PD and a main risk factor in
the development of stroke. To date the research is limited, but nicotine appears to have
differential effects on these immature cells of neural lineage depending on both location
and maturation. Nicotine may exert a protective role for NSCs when exposed to cytotoxic
or inflammatory agents. An effect that may prove useful for future neurorestorative efforts.
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CONCLUSION
There currently remains a paucity of treatment for many neuropathologies resulting from the injury and/or death of neuronal populations. First, we evaluated patient outcomes for the current standard-of-care (i.e. DBS) for advanced movement disorders including PD. Our results indicate that single-staged DBS implant surgeries are non-inferior to the more commonly performed multi-staged surgeries. Affording patients the option to condense their DBS system implantation to a single operation without increasing
complication risk. A protocol that may prove especially favorable for rural or otherwise
underserved populations who often have obstacles surrounding transportation, followup care, etc. Our research developing novel potential therapies for regenerating localized brain lesions, such as striatal degeneration in PD or cortical injury in stroke, was
discussed. Fibrin-based cylindrical implants were shown to effectively recruit endogenous NPCs from their native location to the striatum and/or cortex. Further, these brain
implants were successful in ameliorating motor deficits in a hemiparkinson rodent
model. Lastly, we investigated nicotine’s effect on α4 nAChR expression in dopaminergic and GABAergic neurons within the VTA following passive vapor inhalation. At present we observed a non-statistically significant increase in α4 nAChR expression on female dopaminergic neurons only. Suggesting sex differences in α4 nAChR expression
and AChR functionality within the VTA and other brain regions following nicotine exposure should be further investigated. Nicotine exposure through vapor inhalation is of
particular importance regarding the dramatic increase in e-cigarette use in recent years.
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APPENDIX B
Complications Reported in Other Published Works
No. of
patients
(electrodes)

Staging

Infection

Hardware
Complication

242 (464)

S: 228

S 15
(6.6%
)

NR

AbodeIyamah,
et al. (40)

N: 17

284 (490)
Chen, et
al. (30)

S: 200
N: 84

728 (1333)
Fenoy
(36)

Transitioned from
N to S,
data not
segregated

N1
(5.9%
)
S: 3
(1.5%
)
N: 0
(0%)
23
(3.2%
)

High impedance
S: 1
(0.5%)
N: 1
(1.2%)
Lead malposition 9
(1.2%)

Wound
Dehiscence/
Erosion
S: 9
(4.0%)
N: 0 (0%)

Hemorrhage

Seizures

NR

NR

S: 1 (0.3)
N: 0 (0%)

S: 3
(1.5%)
N: 1
(1.2%)

S: 2
(1%)
N: 2
(2.4%
)

NR

4 (0.5%)

Symptomatic
8
(1.1%)

5
(0.7%
)

29
(4%)

IPG
flipped,
malpositioned or
discomfort 8
(1.1%)

NR

NR

Lead Revision
Sim Bilat:
18
(3.2%)
Staged
Bilat: 20
(12.7%)

Lead migration 4
(0.5%)

Asymptomatic
IVH 25
(3.4%)
ICH 4
(0.5%)

High impedance 4
(0.5%)

Petraglia
(23)

713 (1426)

Sim Bilat:
556
Staged
Bilat: 157
*IPG placement timing
NR

Sim
Bilat:
24
(4.3%
)

Fracture
10 (1.4%)
Sim Bilat:
3 (0.5%)
Staged
Bilat: 0
(0%)

Stage
d
Bilat:
11
(7%)

Loss
of
Efficacy
NR

NR

Sim
Bilat:
16
(2.9%)
Staged
Bilat: 4
(2.5%)

Other

Postoperative
Seroma
S: 1
(0.4%)
N: 0 (0%)

Generator Revision
Sim Bilat:
17
(3.1%)
Staged
Bilat: 6
(3.8%)
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Doshi
(35)

153 (298)

All staged

6
(3.9%
)

Lead malposition 4
(2.6%)

1 (0.7%)

2
(1.3%)

NR

2
(1.3
%)

1 (0.6%)

1
(0.4%)

0
(0%)

NR

Lead migration 0
(0%)
IPG malfunction 2
(1.3%)

Voges, et
al. (33)

262 (472)
*180 (352)
assessed for
long-term
complications

S: 194
(74.1%)

15
(5.7%
)

N: 64
(24.4%)
*data not
segregated

Fracture 0
(0%)
Electrode
damage/fracture 4
((2.2%)
Local discomfort 12
(6.7%)

Seroma
at IPG
site 2
(1.1%)

Electrode
migration 5
(2.8%)

Seijo, et
al. (34)

130 (252)

All staged

Tolleson,
et al. (37)

447 (823)

All staged

Kochanski, et al.
(41)

178 (270)

Falowski,
et al.(38)

432 (606)

Both
Staged and
Nonstaged
procedures
include; not
segregated
S: 326
(475)
N: 106
(131)

2
(1.5%
)
26
(5.8%
)

Connector
displacement 1
(0.6%)
Lead fracture 1
(0.8%)
Lead migration 2
(0.5%)

3
(1.7%
)

Lead and
IPG malfunction 2
(0.5%)
Malpositioned lead
0 (0%)

Noninfected
group 9
(2%)
NR

Lead fractures
S 7 (2.1%)
N 7 (6.6%)

S: 11
(3.4%
)
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IPG implantation site
hematoma 3
(1.25)

NR

9
(6.9%)

13
(10%
)
1
(0.2%
)

NR

CSF leak
1 (0.8%)

Infected
group 8
(1.8%)

2
(0.5%)

NR

Pain
along apparatus 4
(0.9%)

3
(1.7%)

2
(1.1%
)

NR

S: 3
(0.9%)

S: 12
(3.7%)

NR

N: NR

N: 8
(7.5%)

S:
17
(5.2
%)

Extension lead
coiling
S: 2
(0.6%)
N: NR

N: 4
(3.8%
)

Morishita, et
al (39)

132 (138)

All staged

17
(12.9
%)

High impedance
S 5 (1.5%)
N NR
Lead migration
S 1 (0.3%)
N NR
Fracture 7
(5.1%)
Lead migration 16
(12.1%)

N:
NR

NR

Symptomatic
ICH 5
(3.8%)

9
(6.8%
)

NR

Seroma
S: 1
(0.3%)
N: NR

Air embolus 2
(1.5%)

Asymptomatic
ICH 4
(3%)
Total number (% of event by number of patients). S = Staged (IPG implanted in subsequent surgery); N = Nonstaged (DBS system including IPG implanted in one operative session); Sim Bilat = Simultaneous Bilateral (DBS
leads implanted in each hemisphere in one surgery); Staged Bilat = Staged Bilateral (each hemisphere implanted in staged surgeries); NR = Not Reported; ICH = intracranial hemorrhage; IVH = intraventricular hemorrhage
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